

Mina Tadrous

PharmD, MS, PhD

Updated: June 13, 2023

A. Biographical Information

Primary Office Leslie Dan Faculty of Pharmacy - University of Toronto
144 College St.
Toronto, Ontario, Canada
M5S 3M2

1. EDUCATION

Degrees

2010 – 2014 Doctor Of Philosophy (PhD) – Pharmaceutical Sciences, University of Toronto –
Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada
Concentration in Pharmacoepidemiology
Supervisor: Dr. Suzanne Cadarette
Thesis: *Advancing Comparative Effectiveness- Filling in the Gaps for
Bisphosphonates*

2008 – 2010 Masters of Science (MS) – Health Outcomes and Policy Research, University of
Tennessee, Memphis, TN, USA
Supervisor: Dr. Junling Wong
Thesis: *Assessing the sensitivity of the Canadian Adverse Event Following
Immunization Surveillance System*

2004 – 2008 Doctor of Pharmacy (PharmD) – Cum Laude, Albany College of Pharmacy, Albany,
NY

Postgraduate, Research and Specialty Training

2011 – 2012 Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program, CIHR
Training Program in Bridging Scientific Domains for Drug Safety and Effectiveness,
McMaster University - Hamilton, ON, Canada

2008 – 2010 Drug Information and Outcomes Research Residency, University of Tennessee
Health Science Center, MedCommunications Inc and St. Jude Children's Research
Hospital, Memphis, TN, USA
Residency Components:

- Drug Information Center
University of Tennessee Health Science Center; Memphis, TN, USA
Preceptor: Katie Suda, PharmD MS
- Medical Information Specialist
MedCommunications, Inc; Memphis, TN, USA

- Preceptor: Beth Miller, PharmD
- Drug Use Policy and Drug Safety
St. Jude Children’s Research Hospital; Memphis, TN, USA
- Preceptor: James Hoffman, PharmD, MS, BCPS

Qualifications, Certifications and Licenses

2014 – present Pharmacist Licensing – Province of Ontario
2008 – 2014 Pharmacist Licensing – State of Tennessee

2. AFFILIATIONS AND EMPLOYMENT

Appointments

2021 – present University of Toronto- Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada -
Assistant Professor (Tenure Stream, Clinical, Social Administrative Pharmaceutical
Sciences Division)

2019 – present University of Toronto- Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada –
Assistant Professor (Graduate Appointment)

2019 – present University of Waterloo- School of Pharmacy, Waterloo, ON, Canada- Adjunct
Assistant Professor (Graduate Appointment)

2019 – present Women’s College Research Institute, Toronto, ON, Canada –Scientist

2019 – present Ontario Drug Policy Research Network- St. Michael’s Hospital, Toronto, ON, Canada
– Investigator

2019 – present Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada –Adjunct
Scientist (Full Status)

2015 – 2018 University of Toronto- Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada –
Assistant Professor (Lecturer)

2014 – 2019 Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada –Fellow

2014 – 2015 University of Toronto- Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada –
Instructor

2008 – 2010 University of Tennessee College of Pharmacy, Memphis, TN, USA - Adjunct Faculty
–Assistant Professor

Employment

2019 – present Women’s College Hospital Institute for Health System Solutions and Virtual Care
(WIHV), Toronto, ON, Canada –Scientist

2017 – present Expert Consultant on Real-World Evidence and Health Technology Assessment,
Examples: CADTH, WSIB, CEP, Northwest, Toronto, ON, Canada

2014 – 2019 Ontario Drug Policy Research Network- St. Michael’s Hospital, Toronto, ON, Canada
– Research Associate

2014 – 2018 Northwest Telepharmacy, Toronto, ON, Canada – Clinical Hospital Pharmacist

2011 – 2014 Health Clinic Pharmacist – Independent, Toronto, ON, Canada – Clinical Pharmacist

2011 – 2013 MedCommunications, Inc., Memphis, TN, USA – Global Consultant

Mina TADROUS

2010 – present	Community Pharmacist – Independent, Toronto, ON, Canada – Community Pharmacist
2009 – 2010	University of Tennessee Health Science Center – College of Pharmacy, Memphis, TN, USA - Medication-therapy management Pharmacist
2009 – 2010	Methodist –Le Bonheur Healthcare- Methodist North Hospital, Memphis, TN, USA - Staff Pharmacist
2008 – 2011	MedCommunications, Inc., Memphis, TN, USA – Senior Medical Information Specialist

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

Received

INTERNATIONAL

2016	Pharmacoepidemiology and Drug Safety , Best Reviewer
2008	Earl D. Rhodes Memorial Award , General Excellence (Albany College of Pharmacy)
2007	APhA-ASP , Most Innovative Member of the Year Award
2006	Rho Chi Academic Pharmacy Honors Society , Chapter Achievement Award
2006	Phi Lambda Sigma , Pharmacy Leadership Society Award
2002	Lions Club Scholarship , Community Involvement Award

NATIONAL

2023	Emerging Leaders 2023 , Up-and-coming young leaders shaping Canada's economy, culture, and society – Recognition in Healthcare
2022	Association of Faculties of Pharmacy of Canada (AFPC) Awards , AFPC New Investigator Research Award

LOCAL

2022	University of Toronto Leslie Dan Faculty of Pharmacy , CSAP Research Award <i>Total Amount: 10,000 CAD</i>
2021	University of Toronto Leslie Dan Faculty of Pharmacy , Preceptor of the Year Award
2018	University of Toronto Leslie Dan Faculty of Pharmacy , PharmD For Pharmacists Program, Professor of the Year Award
2017	Research Leadership Committee of St. Michael's Hospital , Unsung Hero Award

Teaching and Education Awards

INTERNATIONAL

2009	American College of Clinical Pharmacy Drug Information PRN – Resident Presentation Award, <i>Total Amount: 1,000 USD</i>
------	---

Mina TADROUS

NATIONAL

- 2022 **Association of Faculties of Pharmacy of Canada (AFPC)**, Investigator Research Award
- 2014 **AFPC-CFP Graduate Student Award for Pharmacy Practice Research**, Student Research Award, *Total Amount: 1,500 CAD*
- 2013 -2014 **Pfizer Canada Fellowship in Health Outcomes Research Award**, *Total Amount: 2,700 CAD*
- 2011 **CIHR Fredrick Banting and Charles Best Canada Graduate Scholarship – Doctoral Award**, *Total Amount: 105,000 CAD*
- 2011 **CIHR Training Program in Bridging Scientific Domains for Drug Safety and Effectiveness (DSECT) – Scholarship**, *Total Amount: 35,000 CAD*
- 2011 **Ontario Graduate Scholarship – Declined**, *Total Amount: 10,000 CAD*

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

- 2015 – present The Association of Faculties of Pharmacies of Canada (AFPC)
- 2012 – present International Society of Pharmacoepidemiology
- 2011 – 2015 Canadian Association for Population Therapeutics (CAPT)
- 2010 – present Ontario Pharmacists' Association (OPA)
- 2007 – present Ontario College of Pharmacists (OCP)
- 2008 – 2011 International Society For Pharmacoeconomics and Outcomes Research (ISPOR)
- 2008 – 2010 Memphis Area Pharmacy Society (MAPS)
- 2008 – 2010 Tennessee Pharmacy Association (TPA)
- 2008 – 2010 American Pharmacist Associations (APhA)
- 2008 – 2010 American College of Clinical Pharmacy (ACCP)
- 2006 – 2010 American Society of Health System Pharmacists (ASHP)

Administrative Activities

INTERNATIONAL

International Society of Pharmacoepidemiology (ISPE)

- 2021 – present **Member**, Conference Scientific Planning Committee Member
- 2020 – present **Chair**, Drug Utilization Research Special Interest Group
- 2019 – 2020 **Member**, SEO Subcommittee
- 2015 – 2017 **Chair**, Publication and Communication Committee
- 2013 – present **Member**, Comparative Effectiveness Research, Drug Utilization Research, and Publication Committee
- 2013 – 2014 **Co-President**, University of Toronto Student Chapter

Mina TADROUS

Albany College Of Pharmacy

2006 – 2007 **Student Member**, Curriculum Assessment Committee
2005 – 2006 **Independent Researcher**, Straton Veterans Affairs Medical Centre

Student Government Association (SGA)

2012 – 2014 **Programming Chair**, Executive Committee

NATIONAL

Health Products Supply Chain Advisory Committee

2023 – present **Member**, Advisory Committee

Canadian Association of Population Therapeutics (CAPT)

2021 – present **President**
2020 – present **President-Elect**
2019 – present **Member**, Scientific Advisory Panel
2012 – 2014 **Member**, Student Committee

Health Canada-CADTH Methods Real-World Evidence (RWE)

2019 – present **Chair**, Methods sub-group

Canadian Pharmacists Association (CPhA)

2023 – present **Member**, Consultative Panel for Strategic Planning
2019 – present **Member**, Drug Shortages Advisory Group

Canadian Association of Population Therapeutics (CAPT)

2019 – 2020 **Member**, Board of Directors- Board Member at-large

Joint Health Canada

2018 – present **Core Action Team (CAT) Member**, CADTH Advisory Group on Real-World Evidence (RWE)

PROVINCIAL / REGIONAL

Ontario College of Pharmacists

2023 – present **Member**, Scope of Practice Advisory Group (SPAG)
2021 – present **Member**, Provider Experience Indicator Working Group
2019 – 2020 **Co-Chair**, Pharmacy Indicators Technical Specifications Committee
2019 – 2020 **Member**, Minor Ailments Advisory Group
2012 – 2014 **Member**, Professional Practice Standing Committee

Ontario Pharmacists Association (OPA)

2016 – present **Member**, E-health taskforce

Mina TADROUS

Ontario Ministry of Health

2016 – present **Member**, Ontario Health Information Standards Council (OHISC)

LOCAL

Leslie Dan Faculty of Pharmacy, University of Toronto

2022 – present **Member**, Graduate Research In Progress (GRIP) Committee

2021 – present **Member**, MScPhm Program Committee

2018 – present **Member**, Program Evaluation and Accreditation Committee

2016 – 2017 **Member**, PharmD for Pharmacists Director Search Committee

2015 – present **Member**, PharmD for Pharmacists Faculty Committee

2015 – present **Member**, Critical Appraisal Course Coordinator

University of Toronto

2002 – 2003 **Member**, Student Centre Development Advising Committee

2002 – 2003 **Member**, Academic Advising and Career Centre Steering Committee

2002 – 2003 **Board of Directors and First Year Representative**, Scarborough Campus Student Union

Peer Review Activities

EDITORIAL BOARDS

Member

2022 – present Frontiers in Pharmacology – Advanced Methods in Pharmacovigilance and Pharmacoepidemiology

2022 – present Basic & Clinical Pharmacology & Toxicology

2016 – present Pharmacoepidemiology and Drug Safety

2017 – 2020 Journal of Population Therapeutics and Clinical Pharmacology

2012 – 2014 Journal of Health-System Pharmacy Residents (JHPR)

FUNDING Agencies

Reviewer

2023 Mar Wellcome Trust – Grant Reviewer

2022 Jul Wellcome Trust – Career Development Award Reviewer

2022 Jul Canadian Institute of Health Research (CIHR) – Operating Grant: Clinical Trials Projects Committee, Reviewer

2021 – present Canadian Institute of Health Research (CIHR) – COVID Grant Reviewer

2021 Jun Crohn's and Colitis Canada – Grants-in-Aid of Research Projects

MANUSCRIPT REVIEWS

Reviewer

American Journal of Pharmaceutical Education (AJPE)

Canadian Medical Association Journal (CMAJ)

Mina TADROUS

Pharmacoepidemiology and Drug Safety (PDS)
Canadian Journal of Diabetes (CDJ)
BMC Medical Research Methodology
Journal of Population Therapeutics & Clinical Pharmacology (JPTCP)
Osteoporosis International (OI)
American Journal of Epidemiology (AJE)
Healthcare Policy
Health Affairs
PLoS One
JAMA Network Open
JAMA Internal Medicine

B. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

FUNDED

2023 Feb – 2024 Mar	Co-Applicant. “An international comparative policy analysis of pharmacist-administered long-acting injectable buprenorphine”. Canadian Institute of Health Research (CIHR) Catalyst Grant: Policy Research for Health System Transformation. 149,953 CAD.
2023 Feb – 2024 Mar	Co-Principal Investigator. “Building solutions to address drugs shortages in Canada: developing an evidence-based at-risk medicine list”. Canadian Institute of Health Research (CIHR) Catalyst Grant: Policy Research for Health System Transformation. 149,850 CAD.
2023 Mar – 2024 Apr	Co-Principal Investigator. “Using Real World Data to Determine Chemotherapy Emetogenicity in Pediatric Oncology Patients”. Sick Kids Garron Family Cancer Centre Grant. 59,183 CAD.
2023 Feb – 2027Jan	Co-Applicant. “Deintensifying diabetes management for older adults living in long term care (DIAL): A multi-method study”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 667,024 CAD.
2023 Feb – 2026 Jan	Co-Applicant. “Private infusion care for high-cost biologic medicines: Investigating the implications for the public healthcare system”. Canadian Institute of Health Research (CIHR) Project Grant. 306,001 CAD.
2023 Jan – 2023 Dec	Co-Investigator. “Long-term safety of topical corticosteroids”. National Eczema Association. 100,000 USD.
2022 Apr – 2025 May	Co-Investigator. “The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the

evolving context". Canadian Institute of Health Research (CIHR) Project Grant. 275,400 CAD.

- 2022 Apr – 2024 Dec **Co-Investigator.** "Atrial fibrillation stroke prevention: New insights from anticoagulant adherence thresholds and trajectories". Canadian Institute of Health Research (CIHR) Project Grant. 267,750 CAD.
- 2022 Jan – 2024 Jan **Co-Applicant.** "The impact of COVID-19 and related control measures on the hepatitis C virus care cascade". Canadian Institute of Health Research (CIHR) Operating Grant: Addressing the Health Impacts of COVID-19. 497,320 CAD.
- 2021 Sep – 2022 Oct **Co-Principal-Investigator.** "Investigating the mental health and resiliency of key Canadian health professionals involved in primary, secondary, and tertiary prevention amid the COVID-19 pandemic: A qualitative study to identify and understand work stressors among medical laboratory technologists, pharmacists, occupational therapists, and physiotherapists, and lessons learned to optimize quality of health care". Canadian Institute of Health Research (CIHR) Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021) - Health care systems and services. 120,090 CAD.
- 2021 Sep – 2022 Oct **Co-Principal Investigator.** "Rapid monitoring of the Impact of the COVID-19 pandemic on trends in drug supply and associated clinical outcomes". Canadian Institute of Health Research (CIHR) Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021) - Healthcare Resource Allocation. 489,267 CAD.
- 2021 Sep – 2022 Oct **Co-Applicant.** "The impact of the COVID-19 pandemic on the mental health of children and youth". Canadian Institute of Health Research (CIHR) Operating Grant: Understanding/mitigating impacts of COVID-19 on children, youth & families. 149,844 CAD.
- 2021 Jan – 2022 Feb **Co-Applicant.** "Impact of COVID-19 on Drug Shortages". Department of Health and Human Services – Agency for Healthcare Research and Quality. 400,000 USD.
- 2021 Apr – 2024 May **Co-Applicant.** "Improving the effectiveness of audit and feedback in team-based primary care environments". Canadian Institute of Health Research (CIHR) Operating Grant. 661,726 CAD.
- 2021 Apr – 2022 May **Co-Principal Investigator.** "Safety of systemic treatment in older adults with psoriatic disease." Canadian Institute of Health Research (CIHR) Project Grant. 248,626 CAD.
- 2021 Oct – 2022 Nov **Co-Applicant.** "Ontario's Opioid Drug Observatory: Generating evidence on the evolving opioid crisis to inform and evaluate drug policy and clinical practice in Ontario." Canadian Institute of Health Research (CIHR) Project Grant. 327,500 CAD.
- 2021 Apr – 2024 May **Co-Applicant.** "Population-based studies on drug interactions between opioids and commonly prescribed drugs." Canadian Institute of Health Research (CIHR) Project Grant. 237,150 CAD.
- 2021 Apr – 2022 May **Co-Applicant.** "Big data and little behaviours: audit and feedback with or without a quality improvement toolkit to help primary care facilitate COVID-19 vaccine uptake Health Services and Policy Research." Canadian Institute of Health Research

Mina TADROUS

(CIHR) Operating Grant: Emerging COVID-19 Research Gaps & Priorities. 499,952 CAD.

- 2020 Nov – 2021 Dec **Co-Principal Investigator.** “Safety of systemic treatment in older adults with psoriatic disease”. Canadian Institute of Health Research (CIHR) Project Grant. 100,000 CAD.
- 2020 Jan – 2020 Dec **Co-Investigator.** “Impact of COVID-19 on Prescription Drug Use and Costs among BC Fair Pharmacare Beneficiaries”. BC Ministry of Health COVID-19 Research Priorities. 7,000 CAD.
- 2020 Jan – 2025 Dec **Co-Investigator.** “National Strategy for Digital Health Evaluation”. Health Canada Program Funding. 1,529,744 CAD.
- 2020 Aug – 2021 Sep **Co-Investigator.** “Best practices for pharmacists in medication management for opioid use disorder - expanding access and optimizing integration of care during COVID-19 pandemic and going forward”. Canadian Institute of Health Research (CIHR) Catalyst Grant: Mental Health and COVID-19. 167,795 CAD.
- 2020 Jan – 2020 Dec **Co-Principal Investigator.** “Fractures in older adults with eczema prescribed systemic steroids: two population-based cohort studies” Canadian Dermatology Foundation – World Congress of Dermatology Endowment Award. 100,000 CAD.
- 2020 Jan – 2020 Dec **Collaborator.** “Modeling Cardiovascular Risk of COVID-19 – Insights from the CANHEART Registry”. Ted Rogers Centre for Heart Research Innovation Fund. 100,000 CAD.
- 2020 Jan – 2020 Dec **Principal Investigator.** “Baycrest Integrated Community Care Team Evaluation”. Baycrest Integrated Community Care Team Evaluation – Sub-Grant for Evaluation of Care. 66,780 CAD.
- 2019 Oct – 2022 Nov **Co-Investigator.** “Triangulating Evidence to Evaluate the Impact of Cannabis Policy in Ontario”. Canadian Institute of Health Research (CIHR) Team Grant: Partnerships for Cannabis Policy Evaluation. 509,961 CAD.
- 2019 Sep – Oct 2020 **Co-Principal Investigator.** “The Ontario Program To Improve AntiMicrobial USE (OPTIMISE): Generating knowledge from patients, pharmacists, and physicians to support the implementation of expanding the scope of pharmacist antibiotic prescribing”. Canadian Institute of Health Research (CIHR) Catalyst Grant: Patient Oriented Research. 98,000 CAD.
- 2019 Sep – 2021 Oct **Principal Investigator.** “Real-world effectiveness and cost-effectiveness of novel hepatitis C treatments”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 324,455 CAD.
- 2019 Sep – 2023 Oct **Co-Investigator.** “Understanding and optimizing opioid use in long-term care”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 355,724 CAD.
- 2019 Sep – 2022 Oct **Co-Investigator.** “Optimizing audit and feedback: Personalizing delivery according to team differences”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 592,876 CAD.

Mina TADROUS

- 2019 Sep – 2021 Oct **Co-Investigator.** “Cannabis use and impacts among Ontarians living with HIV in the era of recreational legalization”. Ontario HIV Treatment Network Breaking New Ground Award. 200,264 CAD.
- 2019 Sep – 2021 Oct **Co- Principal Investigator.** “Developing a national Real-world Evidence decision making framework”. Canadian Institute of Health Research (CIHR) Planning and Dissemination Grant. 10,000 CAD.
- 2019 Mar – 2023 Apr **Co-Investigator.** “Psychotropic drug use and safety among children and youth”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 481,952 CAD.
- 2019 Mar – 2021 Apr **Co-Investigator.** “The Ontario Naloxone Program for Pharmacies (ONPP): a multiple method evaluation of naloxone distribution, access, program acceptability, and risk avoidance”. Canadian Institute of Health Research (CIHR) Planning and Dissemination Grants. 100,000 CAD.
- 2018 Jan – 2020 Feb **Co-Investigator.** “Substance Use and Addiction Program (SUAP), Providing appropriate opioid prescription quantities for acute pain management”. Health Canada Project. 357,333 CAD.
- 2018 Jan – 2019 Dec **Co-Principal Investigator.** “Assessing and understanding frailty and high-risk non-prescription drug use in community pharmacy practice”. Canadian Frailty Network – 2017 Catalyst Grant Competition. 79,997 CAD.
- 2017 Jun – 2021 Jul **Co-Investigator.** “Developing a Framework for the Incorporation of Real World Evidence into Cancer Drug Funding Decisions in Canada”. Canadian Institute of Health Research Operating Grant: PHSI for Cancer Control. 970,638 CAD.
- 2016 Oct – 2020 Nov **Co-Investigator.** “Ontario's Opioid Drug Observatory: Leveraging the Narcotics Monitoring System to inform and evaluate provincial drug policy”. Canadian Institute of Health Research (CIHR) Project Scheme Grant. 726,752 CAD.
- 2016 Jan – 2016 Dec **Co-Investigator.** “Application and Reporting of Self-Controlled Study Designs in Pharmacoepidemiology”. International Society of Pharmacoepidemiology (ISPE) Manuscript Support Award. 12,000 CAD.

2. SALARY SUPPORT AND OTHER FUNDING

Personal Salary Support

- 2022 **University of Toronto – Leslie Dan Faculty of Pharmacy, Connaught New Researcher Award.** 20,000 CAD.
- 2011 **CIHR Training Program in Bridging Scientific Domains for Drug Safety and Effectiveness (DSECT), Scholarship.** 35,000 CAD.
- 2011 **CIHR Fredrick Banting and Charles Best Canada Graduate Scholarship, Doctoral Award.** 105,000 CAD.

C. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Huang HC, Li WC, **Tadrous M**, Schumock GT, Touchette D, Awadalla S, Lee TA. Evaluating the use of methods to mitigate bias from non-transient medications in the case-crossover design: a systematic review. *Pharmacoepidemiol Drug Saf.* 2023 Jun 7. doi: 10.1002/pds.5649. Online ahead of print. **Coauthor**
2. Antoniou T, Pritlove C, Shearer D, **Tadrous M**, Shah H, Gomes T. Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study. *Int J Equity Health.* 2023 Jun 6;22(1):112. doi: 10.1186/s12939-023-01924-4. **Coauthor**
3. Gunning R, Chu C, Nakhla N, Kim KC, Suda KJ, **Tadrous M**. Major Shifts in Acid Suppression Drug Utilization After the 2019 Ranitidine Recalls in Canada and United States. *Dig Dis Sci.* 2023 Jun 3. doi: 10.1007/s10620-023-07958-6. Online ahead of print. **Senior Responsible Author**
4. Chayab L, Konstantelos N, Leighl NB, **Tadrous M**, Wong WWL. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). *Pharmacoeconomics.* 2023 Jun 3. doi: 10.1007/s40273-023-01279-2. Online ahead of print. **Coauthor**
5. Zahoor Z, Papadopoulos A, Nowrouzi-Kia B, Ibrahim P, **Tadrous M**, Gohar B. Behind the Counter: Exploring Pharmacists' Stressors and Lessons Learned During the Pandemic in Ontario, Canada. *Health Services Insights.* 2023 May 10. doi:10.1177/11786329231169937. **Coauthor**
6. Antoniou T, Wang T, Pajer K, Gardner W, Lunsky Y, Penner M, **Tadrous M**, Mamdani M, Juurlink DN, Gomes T. Adherence to antipsychotic laboratory monitoring guidelines in children and youth: a population-based study. *Front Psychiatry.* 2023 May 12;14:1172559. doi: 10.3389/fpsy.2023.1172559. eCollection 2023. **Coauthor**
7. Behrouzi B, Sivaswamy A, Chu A, Ferreira-Legere LE, Abdel-Qadir H, Atzema CL, Jackevicius C, Kapral MK, Wijesundera HC, Farkouh ME, Ross HJ, Ha ACT, **Tadrous M**, Paterson M, Gershon AS, Džavík V, Fang J, Kaul P, van Diepen S, Goodman SG, Ezekowitz JA, Bainey KR, Ko DT, Austin PC, McAlister FA, Lee DS, Udell JA. Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, Canada. *JACC Adv.* 2023 May;2(3):100307. doi: 10.1016/j.jacadv.2023.100307. Epub 2023 May 10. **Coauthor**
8. Lofters A, Salahub C, Austin PC, Bai L, Berthelot S, Bhatia RS, Desveaux L, Ivers NM, Kiran T, Maclure M, Martin D, McBrien KA, McCracken R, Paterson JM, Rahman B, Shuldiner J, **Tadrous M**, Thakkar N, Lapointe-Shaw L. Up-to-date on cancer screening among Ontario patients seen by walk-in clinic physicians: A retrospective cohort study. *Prev Med.* 2023 May 6;172:107537. doi: 10.1016/j.ypmed.2023.107537. Online ahead of print. **Coauthor**

9. Zahoor Z, Papadopoulos A, Nowrouzi-Kia B, Ibrahim P, **Tadrous M**, Gohar B. Behind the Counter: Exploring Pharmacists' Stressors and Lessons Learned During the Pandemic in Ontario, Canada. *Health Serv Insights*. 2023 May 2;16:11786329231169937. doi: 10.1177/11786329231169937. eCollection 2023. **Coauthor**
10. Stamenova V, Chu C, Borgundvaag E, Fleury C, Brual J, Bhattacharyya O, **Tadrous M**. Virtual care use prior to emergency department admissions during a stable COVID-19 period in Ontario, Canada. *PLoS One*. 2023 Apr 28;18(4):e0277065. doi: 10.1371/journal.pone.0277065. eCollection 2023. **Senior Responsible Author**
11. Alabaku O, Yang A, Tharmarajah S, Suda K, Vigod S, **Tadrous M**. Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries. *PLoS One*. 2023 Apr 26;18(4):e0284389. doi: 10.1371/journal.pone.0284389. eCollection 2023. **Senior Responsible Author**
12. Lapointe-Shaw L, Kiran T, Salahub C, Austin PC, Berthelo St, Desveaux L, Lofters A, Maclure M, Martin D, McBrien KA, McCracken RK, Rahman B, Schultz SE, Shuldiner J, **Tadrous M**, Bird C, Paterson JM, Bhatia RS, Thakkar NA, Na Y, Ivers NM. Walk-in clinic patient characteristics and utilization patterns in Ontario, Canada: a cross-sectional study. 2023 Apr 25; 11 (2) E345-E356; DOI: <https://doi.org/10.9778/cmajo.20220095>. **Coauthor**
13. Tichy EM, Hoffman JM, **Tadrous M**, Rim MH, Suda K, Cuellar S, Clark JS, Newell MK, Schumock GT. National trends in prescription drug expenditures and projections for 2023 [published online ahead of print, 2023 Apr 24]. *Am J Health Syst Pharm*. 2023;zxad086. doi:10.1093/ajhp/zxad086. **Coauthor**
14. Malik P, Nakhla N, Maxwell CJ, Guo Y, **Tadrous M**, Duqoum A, Hogan DB. Pharmacists' knowledge, perceptions and practices regarding frailty: A cross-sectional survey across practice settings in Canada. *CPJRPC*. 2023 Apr 21; <https://doi.org/10.1177/17151635231164957>. **Coauthor**
15. Kithulegoda N, Chu C, **Tadrous M**, Bean T, Salach L, Regier L, Bevan L, Burton V, Price D, Desveaux L, Ivers NM. Academic detailing to improve appropriate opioid prescribing: A mixed-methods process evaluation. *CMAJ Open*. Accepted [CMAJOpen-2021-0050.R4] 2023 Apr 20. **Coauthor**
16. Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, **Tadrous M**, Wilson K, Wilson SE, Kwong JC, and the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network investigators. Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada. *MedRxiv*. 2023 Apr 11. doi: <https://doi.org/10.1101/2023.04.11.23288403>. **Coauthor**
17. Antoniou T, McCormack D, Kitchen S, Pajer K, Gardner W, Lunskey Y, Penner M, **Tadrous M**, Mamdani M, Juurlink DN, Gomes T. Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment. *Can J Psychiatry*. 2023 Apr 5:7067437231166836. doi: 10.1177/07067437231166836. Online ahead of print. **Coauthor**
18. Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, Beca J, Bouchard S, Chambers C, Hunt MJ, Husereau D, Lungu E, McDonald V, Mercer RE, Mitera G, Muñoz C, Naipaul R, Peacock S, Potashnik T, **Tadrous M**, Takhar P, Taylor M, Trudeau M, Wasney D, Gavura S, Chan KW. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. *Curr. Oncol*. 2023 Mar 28; 30(4), 3776-3786; <https://doi.org/10.3390/currenocol30040286>.

Coauthor

19. Ishaky L, Sivanthan M, **Tadrous M**, Nowrouzi-Kia B, McCarthy L, Papadopoulos A, Gohar B. Pharmacists' Mental Health during the First Two Years of the Pandemic: A Socio-Ecological Scoping Review. *Pharmacy (Basel)*. 2023 Mar 24;11(2):64. doi: 10.3390/pharmacy11020064. **Coauthor**
20. Chen TC, Wettermark B, Steinke D, Caughey GE, **Tadrous M**, Wirtz VJ, Chen LC; Global Opioid Utilization Research Collaborative Group. Feasibility and validity of using healthcare databases to conduct cross-national comparative studies of opioid use, its determinants and consequences. *Pharmacoepidemiol Drug Saf*. 2023 Mar 21. doi: 10.1002/pds.5618. Online ahead of print. **Coauthor**
21. Bowie AC, **Tadrous M**, Thiruchelvam D, Ivers NM, Tanya Mohan T, Tu K, Jaakkimainen L, Drucker AM. A Comparison of Family Physician and Dermatologist Topical Corticosteroid Prescriptions: A Population-Based Cross-Sectional Study. *Journal of the American Academy of Dermatology*. 2023 Mar 11. <https://www.sciencedirect.com/science/article/pii/S0190962223001743>. **Coauthor**
22. Piché-Renaud PP, Swayze S, Buchan SA, Wilson SE, Austin PC, Morris SK, Nasreen S, Schwartz KL, **Tadrous M**, Thampi N, Wilson K, Kwong JC. COVID-19 Vaccine Effectiveness Against Omicron Infection and Hospitalization. *Pediatrics*. 2023 Mar 3;151 (4): e2022059513. <https://doi.org/10.1542/peds.2022-059513>. **Coauthor**
23. Schwartz KL, Wang J, **Tadrous M**, Langford BJ, Daneman N, Leung V, Gomes T, Friedman L, Daley P, Brown KA. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19. *CMAJ*. 2023 Feb 13;195(6):E220-E226. doi: 10.1503/cmaj.221608. **Coauthor**
24. Jorgensen SCJ, Hernandez A, Fell DB, Austin PC, D'Souza R, Guttman A, Brown KA, Buchan SA, Gubbay JB, Nasreen S, Schwartz KL, **Tadrous M**, Wilson K, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. *BMJ*. 2023 Feb 8;380:e074035. doi: 10.1136/bmj-2022-074035. **Coauthor**
25. McClean AR, Cheng L, Bansback N, Clement F, **Tadrous M**, Harrison M, Law MR. Uptake and spending on biosimilar infliximab and etanercept after new start and switching policies in Canada: An interrupted time series analysis. *Arthritis Care Res (Hoboken)*. 2023 Feb 8. doi: 10.1002/acr.25099. Online ahead of print. **Coauthor**
26. Hernandez I, He M, Guo J, **Tadrous M**, Gabriel N, Swabe G, Gellad WF, Essien UR, Saba S, Benjamin EJ, Magnani JW. COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data. *PLoS One*. 2023 Feb 2;18(2):e0281068. doi: 10.1371/journal.pone.0281068. eCollection 2023. **Coauthor**
27. Choi Y, [Santhireswaran A](#), Chu C, Suda KJ, Hernandez I, Magnani JW, **Tadrous M**. Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries. *BMJ Open*. 2023 Jan 27;13(1):e068233. doi: 10.1136/bmjopen-2022-068233. **Senior Responsible Author**
28. Lapointe-Shaw L, Salahub C, Bird C, Bhatia RS, Desveaux L, Glazier RH, Hedden L, Ivers NM, Martin D, Na Y, Spithoff S, **Tadrous M**, Kiran T. Characteristics and Health Care Use of Patients Attending Virtual Walk-in Clinics in Ontario, Canada: Cross-sectional Analysis. *J Med Internet Res*. 2023 Jan 12;25:e40267. doi: 10.2196/40267. **Coauthor**

29. Ledlie S, Gomes T, Dolovich L, Bailey C, Lallani S, Frigault DS, **Tadrous M**. Medication errors in community pharmacies: Evaluation of a standardized safety program. *Explor Res Clin Soc Pharm*. 2023 Jan;9:100218. doi: 10.1016/j.rcsop.2022.100218. eCollection 2023 Mar. **Senior Responsible Author**
30. Antoniou T, McCormack D, Kitchen S, Pajer K, Gardner W, Lunskey Y, Penner M, **Tadrous M**, Mamdani M, Juurlink DN, Gomes T. Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study. *BMC Public Health*. 2023 Jan 11;23(1):85. doi: 10.1186/s12889-022-14677-6. **Coauthor**
31. Lu B, Thomson S, Blommaert S, **Tadrous M**, Earle CC, Chan KKW. Use of Instrumental Variable Analyses for Evaluating Comparative Effectiveness in Empirical Applications of Oncology: A Systematic Review. *J Clin Oncol*. 2022 Dec 13;JCO2200023. doi: 10.1200/JCO.22.00023. Online ahead of print. **Coauthor**
32. Chu C, Brual J, Fang J, Fleury C, Stamenova V, Bhattacharyya O, **Tadrous M**. The Use of Telemedicine in Older-Adults During the COVID-19 Pandemic: a Weekly Cross-Sectional Analysis in Ontario, Canada. *Can Geriatr J*. 2022 Dec 1;25(4):380-389. doi: 10.5770/cgj.25.610. eCollection 2022 Dec. **Senior Responsible Author**
33. Gomes T, Men S, Campbell TJ, **Tadrous M**, Mamdani MM, Paterson JM, Juurlink DN. Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study. *PLoS One*. 2022 Dec 8;17(12):e0278508. doi: 10.1371/journal.pone.0278508. eCollection 2022. **Coauthor**
34. Matthewman J, **Tadrous M**, Mansfield K, Thiruchelvam D, Redelmeier D, Cheung A, Lega I, Prieto-Alhambra D, Cunliffe L, Langan S, Drucker A. 078 Association between oral corticosteroid prescribing patterns and appropriate fracture preventive care: UK and Ontario population-based cohort studies. *Journal of Investigative Dermatology*. 2022 Dec 1. doi: <https://doi.org/10.1016/j.jid.2022.09.088>. **Coauthor**
35. **Tadrous M**, Graili P, Hayes KN, Neville HL, Houlihan J, Clement F, Guertin JR, Law MR, Gomes T. Canadian Trends in Estimated Pharmaceutical Drug Purchases and Projections: 2023. *Canadian Journal of Health Technologies*. 2022 Nov 30. Vol. 2 No. 11 (2022). doi:10.51731/cjht.2022.512. **Principal Author**
36. Konstantelos N, Turchian N, McCormack D, Lecce P, **Tadrous M**, Gomes T. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada. *Drug Alcohol Depend*. 2023 Jan 1;242:109705. doi: 10.1016/j.drugalcdep.2022.109705. Epub 2022 Nov 19. **Coauthor**
37. Chang A, Chaudhry S, McCormack D, Gomes T, Shivji A, **Tadrous M**. Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis. *Can Pharm J (Ott)*. 2022 Oct 12;155(6):326-333. doi: 10.1177/17151635221126481. eCollection 2022 Nov. **Senior Responsible Author**
38. Ho M, **Tadrous M**, Iacono A, Suda K, Gomes T. Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. *J Antimicrob Chemother*. 2022 Nov 14;dkac382. doi: 10.1093/jac/dkac382. Online ahead of print. **Coauthor**

39. Seeto AH, **Tadrous M**, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodriguez AJ. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis. *Bone*. 2022 Nov 10;116610. doi: 10.1016/j.bone.2022.116610. Online ahead of print. **Coauthor**
40. He M, Ferris LK, Gabriel N, **Tadrous M**, Hernandez I. COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data. *J Manag Care Spec Pharm*. 2022 Nov;28(11):1213-1218. doi: 10.18553/jmcp.2022.28.11.1213. **Coauthor**
41. **Tadrous M**, Chung H, Men S, Chu C, Campbell T, Juurlink DN, Kwong JC, Paterson JM, Gomes T. Risk of SARS-CoV-2 infection following initial COVID-19 vaccination: Population-based cohort study. *PLoS One*. 2022 Oct 20;17(10):e0273903. doi: 10.1371/journal.pone.0273903. eCollection 2022. **Principal Author**
42. Savoie-White FH, Tremblay L, Menier CA, Duval C, Bergeron F, **Tadrous M**, Tougas J, Guertin JR, Ugalde PA. The use of early neuromuscular blockage in acute respiratory distress syndrome: A systematic review and meta-analyses of randomized clinical trials. *Heart Lung*. 2022 Oct 12;57:186-197. doi: 10.1016/j.hrtlng.2022.10.001. Online ahead of print. **Coauthor**
43. Chung H, Austin PC, Brown KA, Buchan SA, Fell DB, Fong C, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, **Tadrous M**, Wilson K, Wilson SE, Kwong JC. Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. *Open Forum Infect Dis*. 2022 Sep 7;9(9):ofac449. doi: 10.1093/ofid/ofac449. eCollection 2022 Sep. **Coauthor**
44. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, **Tadrous M**, Wilson K, Wilson SE, Kwong JC. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA Netw Open*. 2022 Sep 1;5(9):e2232760. doi: 10.1001/jamanetworkopen.2022.32760. **Coauthor**
45. Khouja T, **Tadrous T**, Suda KJ. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)—authors' response. 2022 Aug 18. *Journal of Antimicrobial Chemotherapy*, Volume 77, Issue 10, October 2022, Pages 2889–2890, <https://doi.org/10.1093/jac/dkac274>. **Coauthor**
46. Evans WK, Takhar P, McDonald V, Elias M, Binder L, Michaud S, **Tadrous M**, Muñoz C, Chan KKW. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned. *Curr Oncol*. 2022 Aug 7;29(8):5616-5626. doi: 10.3390/currncol29080443. **Coauthor**
47. Khouja T, **Tadrous M**, Suda KJ. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)-authors' response. *J Antimicrob Chemother*. 2022 Aug 18;dkac274. doi: 10.1093/jac/dkac274. Online ahead of print. **Coauthor**
48. Iacono A, Campitelli MA, Bronskill SE, Hogan DB, Iaboni A, Maclagan LC, Gomes T, **Tadrous M**, Evans C, Gruneir A, Guan Q, Hadjistavropoulos T, Cotton C, Gill SS, Seitz DP, Ho J, Maxwell CJ. Correlates of Opioid Use Among Ontario Long-Term Care Residents and Variation by Pain Frequency and Intensity: A Cross-sectional Analysis. *Drugs Aging*. 2022 Aug 17:1-17. doi: 10.1007/s40266-022-00972-9. Online ahead of print. **Coauthor**
49. Nasreen S, Febriani Y, Velásquez García HA, Zhang G, **Tadrous M**, Buchan SA, Righolt CH, Mahmud SM, Janjua NZ, Kraiden M, De Serres G, Kwong JC. Effectiveness of COVID-19 vaccines against

hospitalization and death in Canada: A multiprovincial test-negative design study. *Clin Infect Dis*. 2022 Aug 17;ciac634. doi: 10.1093/cid/ciac634. Online ahead of print. **Coauthor**

50. Matthewman J, **Tadrous M**, Mansfield K, Thiruchelvam D, Redelmeier D, Cheung A, Lega I, Prieto-Alhambra D, Cunliffe L, Langan S, Drucker A. 331 Association between oral corticosteroid prescribing patterns and appropriate fracture preventive care in people with atopic eczema in the UK. 2022 Aug 1. *Journal of Investigative Dermatology*. doi:<https://doi.org/10.1016/j.jid.2022.05.340>. **Coauthor**
51. Shakeri A, Chu C, Stamenova V, Fang J, Barker LC, Vigod SN, Bhatia RS, **Tadrous M**. Comparison of Healthcare Utilization between Telemedicine and Standard Care: A Propensity-score Matched Cohort Study Among Individuals with Chronic Psychotic Disorders in Ontario, Canada. *Schizophrenia Bulletin Open*. July 2022. doi:10.1093/schizbullopen/sgac046. **Senior Responsible Author**
52. Chu C, Stamenova V, Fang J, Shakeri A, **Tadrous M**, Bhatia RS. The association between telemedicine use and changes in healthcare utilization and outcomes in patients with congestive heart failure: a retrospective cohort study. *JMIR Cardio*. 2022 Jul 21. doi: 10.2196/36442. Online ahead of print. **Coauthor**
53. Harris DA, Guo Y, Nakhla N, **Tadrous M**, Hogan DB, Hennessy D, Langlois K, Garner R, Leslie S, Bronskill SE, Heckman G, Maxwell CJ. Prevalence of prescription and non-prescription polypharmacy by frailty and sex among middle-aged and older Canadians. *Health Rep*. 2022 Jun 15;33(6):3-16. doi: 10.25318/82-003-x202200600001-eng. **Coauthor**
54. McClean AR, Law MR, Harrison M, Bansback N, Gomes T, **Tadrous M**. Adoption des médicaments biosimilaires au Canada : analyse des politiques provinciales et données sur leur utilisation. *CMAJ*. 2022 Jun 27;194(25):E891-E896. doi: 10.1503/cmaj.211478-f. **Senior Responsible Author**
55. Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwachai W, Habbous S, **Tadrous M**, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW. Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer. *JNCI Cancer Spectr*. 2022 Jun 27:pkac047. doi: 10.1093/jncics/pkac047. Online ahead of print. **Coauthor**
56. Xie J, Strauss VY, Collins GS, Khalid S, Delmestri A, Turkiewicz A, Englund M, **Tadrous M**, Reyes C, Prieto-Alhambra D. Trends of Dispensed Opioids in Catalonia, Spain, 2007–19: A Population-Based Cohort Study of Over 5 Million Individuals. *Front. Pharmacol.*, 2022 June 9. <https://doi.org/10.3389/fphar.2022.912361>. **Coauthor**
57. Lau B, **Tadrous M**, Chu C, Hardcastle L, Beall RF. COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022. *CMAJ*. 2022 Jun 13;194(23):E801-E806. doi: 10.1503/cmaj.212070. **Coauthor**
58. Dyrda P, Vannabouathong C, Peter K, Bansback N, **Tadrous M**. Utilization of Old- Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada. *Canadian Journal of Health Technologies*. 2022 Jun 10. Vol. 2 No. 6: doi: <https://doi.org/10.51731/cjht.2022.356>. **Senior Responsible Author**
59. Bowie AC, **Tadrous M**, Egeberg A, Harvey J, Lax SJ, Thyssen JP, Drucker AM. Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems. *JAMA Dermatol*. 2022 May 25. doi: 10.1001/jamadermatol.2022.1706. Online ahead of print. **Coauthor**

60. Neu S, Locke JL, Matta R Troke N, **Tadrous M**, Saskin R, Nam R, Herschorn S. MP18-14 Metformin in the treatment of overactive bladder—a retrospective nesting case-control, population based analysis. *Journal of the American Urological Association*. 2022 May 1. <https://doi.org/10.1097/JU.0000000000002551.14>. **Coauthor**
61. Hofmeister M, Sivakumar A, Clement F, Hayes KN, Law M, Guertin JR, Neville HL, **Tadrous M**. Trends in Canadian prescription drug purchasing: 2001–2020. *Journal of Pharmaceutical Policy and Practice*. 2022 Mar;15(1). doi: 10.1186/s40545-022-00420-4. **Senior Responsible Author**
62. Antoniou T, Men S, **Tadrous M**, Leece P, Munro C, Gomes T. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. *Drug Alcohol Depend*. 2022 Apr 26;236:109473. doi: 10.1016/j.drugalcdep.2022.109473. Online ahead of print. **Coauthor**
63. Antoniou T, McCormack D, **Tadrous M**, Juurlink DN, Gomes T. The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study. *Front Pharmacol*. 2022 Apr 20;13:861953. doi: 10.3389/fphar.2022.861953. eCollection 2022. **Coauthor**
64. Garg R, Kitchen SA, Men S, Campbell TJ, Bozinoff N, **Tadrous M**, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis. *Drug Alcohol Depend*. 2022 Apr 14;236:109459. doi: 10.1016/j.drugalcdep.2022.109459. Online ahead of print. **Coauthor**
65. Konstantelos N, Shakeri A, McCormack D, Campos-Meade A, Gomes T, Murti M, Pierre-Pierre V, **Tadrous M**. Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study. *Can Commun Dis Rep*. 2022 Apr 6;48(4):179-180. doi: 10.14745/ccdr.v48i04a08. eCollection 2022 Apr 6. **Senior Responsible Author**
66. Stamenova V, Chu C, Pang A, Fang J, Shakeri A, Cram P, Bhattacharyya O, Bhatia RS, **Tadrous M**. Virtual care use during the COVID-19 pandemic and its impact on healthcare utilization in patients with chronic disease: A population-based repeated cross-sectional study. *PLoS One*. 2022 Apr 25;17(4):e0267218. doi: 10.1371/journal.pone.0267218. eCollection 2022. **Senior Responsible Author**
67. Gomes T, Kim KC, Suda KJ, Garg R, **Tadrous M**. International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. *Pharmacoepidemiol Drug Saf*. 2022 Apr 23. doi: 10.1002/pds.5443. Online ahead of print. **Senior Responsible Author**
68. McClean AR, Law MR, Harrison M, Bansback N, Gomes T, **Tadrous M**. Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. *CMAJ*. 2022 Apr 19;194(15):E556-E560. doi: 10.1503/cmaj.211478. **Senior Responsible Author**
69. Fralick M, Martins D, **Tadrous M**, Gomes T. Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. *Can J Hosp Pharm*. 2022 Apr;75(2):104-107. doi: 10.4212/cjhp.v75i2.3066. Epub 2022 Apr 4. **Coauthor**
70. Tichy EM, Hoffman JM, Suda KJ, Rim MH, **Tadrous M**, Cuellar S, Clark JS, Ward J, Schumock GT. National trends in prescription drug expenditures and projections for 2022. *Am J Health Syst Pharm*. 2022 Apr 6;zxac102. doi: 10.1093/ajhp/zxac102. Online ahead of print. **Coauthor**

71. Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, **Tadrous M**, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. *Curr Oncol*. 2022 Mar 17;29(3):2046-2063. doi: 10.3390/currenocol29030165. **Coauthor**
72. Crosby M, von den Baumen TR, Chu C, Gomes T, Schwartz KL, **Tadrous M**. Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study. *CMAJ Open*. 2022 Mar 22;10(1):E262-E268. doi: 10.9778/cmajo.20210095. Print 2022 Jan-Mar. **Senior Responsible Author**
73. Hofmeister M, Sivakumar A, Clement F, Hayes KN, Law M, Guertin JR, Neville HL, **Tadrous M**. Trends in Canadian prescription drug purchasing: 2001-2020. *J Pharm Policy Pract*. 2022 Mar 17;15(1):20. doi: 10.1186/s40545-022-00420-4. **Senior Responsible Author**
74. Boone CG, Bishop AC, Ivers N, Desveaux L, **Tadrous M**. Audit and feedback in community pharmacy: An untapped strategy of quality improvement. *Can Pharm J (Ott)*. 2021 Nov 5;155(2):79-81. doi: 10.1177/17151635211056528. eCollection 2022 Mar-Apr. **Senior Responsible Author**
75. Makari J, Dagenais J, **Tadrous M**, Jennings S, Rahmaan I, Hayes K. Hospital pharmacist discharge care is independently associated with reduced risk of readmissions for patients with chronic obstructive pulmonary disease: A propensity-matched cohort study. *Can Pharm J (Ott)*. 2021 Dec 10;155(2):101-106. doi: 10.1177/17151635211061141. eCollection 2022 Mar-Apr. **Coauthor**
76. Kitchen SA, Campbell TJ, Mena S, Bozinoff N, **Tadrous M**, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. *International Journal of Drug Policy*. 2022 May;103. doi: 10.1016/j.drugpo.2022.103644. **Coauthor**
77. Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, **Tadrous M**, Munro C, Antoniou T, Werb D, Wyman J. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. *JAMA*. 2022 Mar 1;327(9):846-855. doi: 10.1001/jama.2022.1271. **Coauthor**
78. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Kevin L. Schwartz KL, Sundaram ME, **Tadrous M**, Wilson K, Wilson SE, Kwong JC. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. *medRxiv*. 2022 Jan. doi: 10.1101/2021.12.30.21268565. **Coauthor**
79. Shuldiner J, Schwartz KL, Langford BJ, **Ivers NM** and on behalf of the Ontario Healthcare Implementation Laboratory study team. Optimizing responsiveness to feedback about antibiotic prescribing in primary care: protocol for two interrelated randomized implementation trials with embedded process evaluations. *Implementation Science*. 2022 Feb 14. doi: 10.1186/s13012-022-01194-8. **Coauthor**
80. Gomes T, McCormack D, Bozinoff N, **Tadrous M**, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B. Duration of use and patient outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: A population-based propensity-score matched cohort study. *Addiction*. 2022 Mar 8. doi: 10.1111/add.15862. Online ahead of print. **Coauthor**

81. Khouja T, Mitsantisuk K, **Tadrous M**, Suda KJ. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). *J Antimicrob Chemother.* 2022 Feb 18;dkac028. doi: 10.1093/jac/dkac028. Online ahead of print. **Coauthor**
82. Rolf von den Baumen T, **Tadrous M**, Schwartz KL, Gomes T. Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019-authors' response. *J Antimicrob Chemother.* 2022 Feb 15;dkac033. doi: 10.1093/jac/dkac033. Online ahead of print. **Coauthor**
83. Hernandez I, Gabriel N, He M, Guo J, **Tadrous M**, Suda KJ, Magnani JW. Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis. *Am Heart J Plus.* 2022 Jan;13:100096. doi: 10.1016/j.ahjo.2022.100096. Epub 2022 Feb 4. **Coauthor**
84. Hernandez I, Gabriel N, He M, Guo J, **Tadrous M**, Suda KJ, Magnani JW. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *Am Heart J Plus.* 2022 Jan;13:100096. doi: 10.1016/j.ahjo.2022.100096. Epub 2022 Feb 4. **Coauthor**
85. Schneider T, Gomes T, Hayes KN, Suda KJ, **Tadrous M**. Comparisons of Insulin Spending and Price Between Canada and the United States. *Science Direct.* 2022 Feb 5. <https://doi.org/10.1016/j.mayocp.2021.11.028>. **Senior Responsible Author**
86. Suda KJ, Kim KC, Hernandez I, Gellad WF, Rothenberger S, Campbell A, Malliart L, **Tadrous M**. The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. *J Am Pharm Assoc (2003).* 2021 Dec 24;S1544-3191(21)00563-X. doi: 10.1016/j.japh.2021.12.014. Online ahead of print. **Senior Responsible Author**
87. Gomes T, McCormack D, Kitchen SA, Paterson JM, Mamdani MM, Proulx L, Bayliss L, **Tadrous M**. Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. *CMAJ Open.* 2021 Nov 23;9(4):E1055-E1062. doi: 10.9778/cmajo.20210091. Print 2021 Oct-Dec. **Senior Responsible Author**
88. Uthayakumar S, **Tadrous M**, Vigod SN, Kitchen SA, Gomes T. The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. *Depress Anxiety.* 2021 Nov 29. doi: 10.1002/da.23228. Online ahead of print. **Coauthor**
89. Zeitouny S, Suda KJ, Mitsantisuk K, Law MR, **Tadrous M**. Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis. *BMJ Glob Health.* 2021 Dec;6(12):e006874. doi: 10.1136/bmjgh-2021-006874. **Senior Responsible Author**
90. Fenna J, Chu C, Hassan R, Gomes T, **Tadrous M**. Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. *CMAJ Open.* 2021 Dec 7;9(4):E1128-E1133. doi: 10.9778/cmajo.20200232. Print 2021 Oct-Dec. **Senior Responsible Author**
91. **Tadrous M**, Daniels B, Pearson SA, Gomes T. Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. *CMAJ Open.* 2021 Nov 23;9(4):E1048-E1054. doi: 10.9778/cmajo.20200291. Print 2021 Oct-Dec. **Principal Author**

92. Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, **Tadrous M**, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. *Curr Oncol*. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392. **Coauthor**
93. Boone CG, Antoniou T, Juurlink DN, von den Baumen TR, Kitchen SA, Richards GC, **Tadrous M**, Gomes T. The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. *CMAJ Open*. 2021 Dec 14;9(4):E1181-E1186. doi: 10.9778/cmajo.20210173. Print 2021 Oct-Dec. **Coauthor**
94. Hernandez I, Gabriel N, He M, Guo J, **Tadrous M**, Suda KJ, Magnani JW. COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data. *J Am Heart Assoc*. 2021 Dec 21;10(24):e023235. doi: 10.1161/JAHA.121.023235. Epub 2021 Dec 16. **Coauthor**
95. Boone CG, Bishop AC, Ivers NM, Desveaux L, **Tadrous M**. Audit and feedback in community pharmacy: An untapped strategy of quality improvement. *Canadian Pharmacists Journals*. 2021 Nov 5. <https://doi.org/10.1177/17151635211056528>. **Senior Responsible Author**
96. Bouck Z, Tricco AC, Rosella LC, Ling V, Gomes T, **Tadrous M**, Fox MP, Scheim AI, Werb D. Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. *Epidemiology*. 2021 Nov 12. doi: 10.1097/EDE.0000000000001443. Online ahead of print. **Coauthor**
97. Pottegård A, Morin L, Hallas J, Gerhard T, Winterstein AG, Perez-Gutthann S, **Tadrous M**. Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. *Pharmacoepidemiol Drug Saf*. 2021 Nov 4. doi: 10.1002/pds.5382. Online ahead of print. **Senior Responsible Author**
98. **Tadrous M**, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, Gomes T. Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. *JAMA Network Open*. 2021 Oct 1;4(10):e2130795. doi: 10.1001/jamanetworkopen.2021.30795. **Senior Responsible Author**
99. Xie J, Strauss VY, Martinez-Laguna D, Carbonell-Abella C, Diez-Perez A, Nogues X, Collins GS, Khalid S, Delmestri A, Turkiewicz A, Englund M, **Tadrous M**, Reyes C, Prieto-Alhambra D. Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. *JAMA*. 2021 Oct 19;326(15):1504-1515. doi: 10.1001/jama.2021.15255. **Coauthor**
100. **Tadrous M**, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, Gomes T. Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. *JAMA Netw Open*. 2021 Oct 1;4(10):e2130795. doi: 10.1001/jamanetworkopen.2021.30795. **Principal Author**
101. Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, **Tadrous M**, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. *MDPI Current Oncology*. 2021 October 16. <https://www.mdpi.com/1718-7729/28/5/354/htm>. **Coauthor**

102. Hayes KN, Gomes T, **Tadrous M**. Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. *Front Pharmacol*. 2021 Aug 6;12:709349. doi: 10.3389/fphar.2021.709349. eCollection 2021. **Senior Responsible Author**
103. **Tadrous M**, Loncar M, Dyrda P. Utilization Patterns of Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Rationale for Improving the Harmonization of Coverage Criteria. *Canadian Journal of Health Reviews*. 2021 Aug 23. doi: <https://doi.org/10.51731/cjht.2021.133>. **Principal Author**
104. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta NE, Mahmud SM, Righolt CH, Svenson LW, MacDonald SE, Janjua NZ, **Tadrous M**, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ*. 2021 Aug 20;374:n1943. doi: 10.1136/bmj.n1943. **Coauthor**
105. Callaway Kim K, **Tadrous M**, Kane-Gill SL, Barbash IJ, Rothenberger S, Suda KJ. Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. *Chest*. 2021 Aug 11:S0012-3692(21)03632-1. doi: 10.1016/j.chest.2021.08.007. Online ahead of print. **Coauthor**
106. Shakeri A, Konstantelos N, Chu C, Antoniou T, Feld J, Suda KJ, **Tadrous M**. Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. *Viruses*. 2021 Jul 7;13(7):1314. doi: 10.3390/v13071314. **Senior Responsible Author**
107. Campitelli MA, Bronskill SE, Maclagan LC, Harris DA, Cotton CA, **Tadrous M**, Gruneir A, Hogan DB, Maxwell CJ. Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. *JAMA Netw Open*. 2021 Aug 2;4(8):e2118441. doi: 10.1001/jamanetworkopen.2021.18441. **Coauthor**
108. Martins D, Khuu W, **Tadrous M**, Greaves S, Sproule B, Bozinoff N, Juurlink DN, Mamdani MM, Paterson M, Gomes T. Impact of Changes in Opioid Funding and Clinical Policies on Rapid Tapering of Opioids in Ontario, Canada. *PAIN*. 2021 Jul 28. doi: 10.1097/j.pain.0000000000002420. Online ahead of print. **Coauthor**
109. Davenport Hoyer L, Desveaux L, Nakhla N, Maxwell C, **Tadrous M**. 'Fitting in the pharmacist' - a qualitative analysis of the perceived relationship between community pharmacists and older adults with complex care needs. *Int J Pharm Pract*. 2021 Jul 9:riab034. doi: 10.1093/ijpp/riab034. Online ahead of print. **Senior Responsible Author**
110. Rolf von den Baumen T, Crosby M, **Tadrous M**, Schwartz KL, Gomes T. Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. *J Antimicrob Chemother*. 2021 Jul 5:dkab205. doi: 10.1093/jac/dkab205. **Coauthor**
111. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, Austin PC, Schwartz KL, Sundaram ME, Calzavara A, Chen B, **Tadrous M**, Wilson K, Wilson SE, Kwong JC. Effectiveness of COVID-19 vaccines against variants of concern, Canada. July 2021. *MedRxiv*. doi:10.1101/2021.06.28.21259420. **Coauthor**

Mina TADROUS

112. Khouja T, **Tadrous M**, Matusiak L, Suda K. Opioid Prescribing in United States Health Systems, 2015 to 2019. June 2021. Value in Health. doi:10.1016/j.jval.2021.04.1274. **Coauthor**
113. Rahmatian D, **Tadrous M**. Old dog with new tricks: An introduction to real-world evidence for pharmacists. Am J Health Syst Pharm. 2021 Jun 21;zxab261. doi: 10.1093/ajhp/zxab261. Online ahead of print. **Senior Responsible Author**
114. Lam M, Zhu J, **Tadrous M**, Drucker AM. 232 The association between topical calcineurin inhibitor use and risk of cancer: A systematic review and meta-analysis. May 2021. Journal of Investigative Dermatology 141(5):S42. DOI:10.1016/j.jid.2021.02.254. **Coauthor**
115. Konstantelos N, Shakeri A, McCormack D, Jordan J, Gomes T, **Tadrous M**. Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. April 2021. The American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001287. **Senior Responsible Author**
116. Tichy EM, Hoffman JM, Suda KJ, Rim MH, **Tadrous M**, Cuellar S, Clark JS, Wiest MD, Matusiak LM, Schumock GT. National trends in prescription drug expenditures and projections for 2021. Am J Health Syst Pharm. 2021 Apr 21;zxab160. doi: 10.1093/ajhp/zxab160. Online ahead of print. **Coauthor**
117. Suda KJ, **Tadrous M**. Sum of the parts: Ensuring a resilient global drug supply chain. Infect Control Hosp Epidemiol. 2021 May;42(5):598-599. doi: 10.1017/ice.2021.138. Epub 2021 Mar 29. **Coauthor**
118. Cadarette SM, Maclure M, Delaney JAC, Whitaker HJ, Hayes KN, Wang SV, **Tadrous M**, Gagne JJ, Consiglio GP, Hallas J. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):671-684. doi: 10.1002/pds.5227. Epub 2021 Apr 1. **Coauthor**
119. Hernandez I, **Tadrous M**, Magnani JW, Guo J, Suda KJ. Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. Am J Cardiovasc Drugs. 2021 Mar 26:1-3. doi: 10.1007/s40256-021-00475-9. Online ahead of print. **Coauthor**
120. Stamenova V, Chu C, Pang A, **Tadrous M**. Using administrative data to explore potentially aberrant provision of virtual care during COVID-19: a retrospective cohort study of Ontario provincial data. JMIR. April 2021. doi:10.2196/preprints.29396. **Senior Responsible Author**
121. Fenna J, McCormack D, Kitchen S, Martins D, Gomes T, **Tadrous M**. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. J Manag Care Spec Pharm. 2021 Apr;27(4):444-452. doi/full/10.18553/jmcp.2021.27.4.444. **Senior Responsible Author**
122. Chu C, Cram P, Pang A, Stamenova V, **Tadrous M**, Bhatia RS. Rural Telemedicine Use Before and During the COVID-19 Pandemic: Repeated Cross-sectional Study. J Med Internet Res. 2021 Apr 5;23(4):e26960. doi: 10.2196/26960. **Coauthor**
123. Lam M, Zhu JW, **Tadrous M**, Drucker AM. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021 May 1;157(5):549-558. doi: 10.1001/jamadermatol.2021.0345. **Coauthor**
124. Milakovic M, Corrado AM, **Tadrous M**, Nguyen ME, Vuong S, Ivers NM. Effects of a single-entry intake system on access to outpatient visits to specialist physicians and allied health professionals: a

systematic review. *CMAJ Open*. 2021 Apr 16;9(2):E413-E423. doi: 10.9778/cmajo.20200067. Print 2021 Apr-Jun. **Coauthor**

125. Hayes KN, Burkard T, Weiler S, **Tadrous M**, Burden AM. Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. *Eur J Gastroenterol Hepatol*. 2021 Apr 21. doi: 10.1097/MEG.0000000000002173. **Coauthor**
126. Sundaram M, Nasreen S, Calzavara A, He S, Chung H, Bronskill SE, Buchan SA, **Tadrous M**, Tanuseputro P, Wilson K, Wilson S, Kwong JC. Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments. *MedRxiv*. March 2021. doi:10.1101/2021.03.17.21253290. **Coauthor**
127. Bhatia RS, Chu C, Pang A, **Tadrous M**, Stamenova V, Cram P. Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. *CMAJ Open*. 2021 Feb 17;9(1):E107-E114. doi: 10.9778/cmajo.20200311. Print 2021 Jan-Mar. **Coauthor**
128. Martins D, McCormack D, **Tadrous M**, Gomes T, Kwong JC, Mamdani MM, Buchan SA, Antoniou T. Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. *Clin Infect Dis*. 2021 Jan 27;72(2):279-284. **Coauthor**
129. Shakeri A, Gomes T, Suda K, **Tadrous M**. Choppy Waters: The Importance of Accounting for Shifting Drug Utilization During the COVID-19 Pandemic in Future Observational Drug-related Studies. *Basic Clin Pharmacol Toxicol*. 2021 Feb 6. Epub ahead of print. **Senior Responsible Author**
130. Antoniou T, Pritlove C, Shearer D, Martins D, **Tadrous M**, Munro C, Gomes T. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. *Int J Drug Policy*. 2021 Feb 7:103146. Epub ahead of print. **Coauthor**
131. Lam M, Zhu J, **Tadrous M**, Drucker AM. The association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma and melanoma. *JAMA Dermatology*. Accepted Feb 2, 2021. **Coauthor**
132. Campbell, T., Martins, D., **Tadrous, M.**, Juurlink, D.N., Paterson, J.M., Mamdani, M.M., Mock, D., Gomes, T. Dental opioid prescription characteristics and the risk of new, persistent use. *American Journal of Preventive Medicine*. 2021 June 60(6): 831-839. **Coauthor**
133. Soobiah C, Phung M, **Tadrous M**, Jamieson T, Bhatia RS, Desveaux L. Understanding engagement and potential impact of an electronic drug repository: A mixed-methods study. *JMIR Formative Research*. Jan 14, 2021. DOI:10.2196/preprints.27158. **Coauthor**
134. Chung H, He S, Sharifa N, Sundaram M, Buchan S, Wilson S, Chen B, Calzavara A, Fell D, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta N, Mahmud S, Righolt C, Svenson L, MacDonald S, Janjua N, **Tadrous M**, Kwong JC. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines Against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario, Canada. January 2021. *SSRN Electronic Journal*. DOI:10.2139/ssrn.3845993. **Coauthor**
135. Tang E, Maqbool T, Lam M, Adam G, **Tadrous M**, Rochon PA, Drucker AM. Safety of systemic medications among older adults with psoriasis and atopic dermatitis: a systematic review of observational studies. Accepted (Jan 2020) - *Journal of Cutaneous Medicine & Surgery*. **Coauthor**

Mina TADROUS

136. Shakeri A, Hayes K, Gomes T, **Tadrous M**. Comparison of Public and Private Payments for Direct-Acting Antivirals (DAAs) Across Canada. Accepted (January 2021)- Canadian Liver Journal. **Senior Responsible Author**
137. Milakovic M, Corrado A, **Tadrous M**, Nguyen M, Vuong S, Ivers N. The impact of a single-entry intake system on access to outpatient specialist visits: A systematic review. Accepted (December 2020)- CMAJOpen. **Coauthor**
138. Antoniou T, Martins D, Campbell T, **Tadrous M**, Munro C, Leece P, Mamdani M, Juurlink DN, Gomes T. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: A population-based time series analysis. Addiction. 2020 Nov 18. **Coauthor**
139. **Tadrous M**, Mason K, Dodd Z, Guyton M, Powis J, McCormack D, Gomes T. Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. Canadian Liver Journal. :e20200025. **Principal Author**
140. Gomes T, Campbell T, **Tadrous M**, Mamdani MM, Paterson JM, Juurlink DN. (2020), Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. Pharmacoepidemiol Drug Saf. **Coauthor**
141. Shakeri A, Zhang M, **Tadrous M**. The missed opportunity for real-world evidence to shape our understanding of medical cannabis. Br J Clin Pharmacol. 2020 Oct 18. doi: 10.1111/bcp.14550. Epub ahead of print. **Senior Responsible Author**
142. Lake J, Brown T, Vu K, **Tadrous M**. Comparison of admission rates to a non-traditional Doctor of Pharmacy programme using internet- based multiple-mini interviews versus on-site. Pharmacy Education. 2020 Sep; 20(1): 282 – 286. **Senior Responsible Author**
143. Shakeri A, Srimurugathan N, Suda KJ, Gomes T, **Tadrous M**. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value Health. 2020 Sep;23(9):1137-1141. **Senior Responsible Author**
144. Crosby M, **Tadrous M**, Gomes T. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. Clin Pharmacol Ther. 2020 Sep. **Coauthor**
145. Antoniou T, McCormack D, Campbell T, Sutradhar R, **Tadrous M**, Lum-Wilson N, Leece P, Munro C, Gomes T. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. Drug Alcohol Depend. 2020 Aug 19;216:108238. **Coauthor**
146. Mukovozov IM, Morra DE, Giustini D, **Tadrous M**, Cheung AM, Drucker AM. Atopic Dermatitis and Bone Health: A Systematic Review. J Eur Acad Dermatol Venereol. 2020 Aug. **Coauthor**
147. Lam M, Zhu JW, Maqbool T, Adam G, **Tadrous M**, Rochon P, Drucker AM. Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2020 Aug. **Coauthor**
148. Drucker AM, **Tadrous M**. Topical Calcineurin Inhibitors and Skin Cancer-Another Piece of the Puzzle. JAMA Dermatol. 2020 Aug. **Senior Responsible Author**

Mina TADROUS

149. deSouza IS, **Tadrous M**, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. *Ann Emerg Med*. 2020 Jul;76(1):14-30. **Coauthor**
150. **Tadrous M**, Ahuja T, Ghosh B, Kropp R. Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle. *Health Policy*. 2020;15(4):41-47. **Principal Author**
151. **Tadrous M**, Martins D, Mamdani MM, Gomes T. Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. *CMAJ open*. 2020 Apr 1;8(2):E297-303. **Principal Author**
152. Maclagan LC, Visanji NP, Cheng Y, **Tadrous M**, Lacoste AM, Kalia LV, Bronskill SE, Marras C. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. *Pharmacoepidemiol Drug Saf*. 2020 Aug;29(8):864-872. **Coauthor**
153. **Tadrous M**, Fung K, Desveaux L, Gomes T, Taljaard M, Grimshaw JM, Bell CM, Ivers NM. Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial. *JAMA network open*. 2020 May 1;3(5):e205724. **Principal Author**
154. Tichy EM, Schumock GT, Hoffman JM, Suda KJ, Rim MH, **Tadrous M**, Stubbings J, Cuellar S, Clark JS, Wiest MD, Matusiak LM. National trends in prescription drug expenditures and projections for 2020. *Am J Health Syst Pharm*. 2020 Jul 23;77(15):1213-1230. **Coauthor**
155. deSouza IS, **Tadrous M**, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: A Systematic Review and Network Meta-analysis. *Euorpace*. 2020 Jun 1;22(6):854-869. **Coauthor**
156. Wong L, **Tadrous M**. Topical Corticosteroids and Type 2 Diabetes Mellitus: A Critical Appraisal. *Br J Dermatol*. 2020 Jul;183(1):37-38. **Senior Responsible Author**
157. Chan K, Nam S, Evans B, deOliveira C, Chambers A, Gavura S, Hoch J, Mercer RE, Dai WF, Beca J, **Tadrous M**, Isaranuwatthai W. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. *BMJ open*. 2020 Jan 7;10(1):e032884. **Coauthor**
158. Guan Q, Campbell T, Martins D, **Tadrous M**, Juurlink D, Paterson JM, et al. Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. *J Am Dent Assoc*. 2020 Jan;151(1):43-50. **Coauthor**
159. **Tadrous M**, Knowles S, Ruddock B, Oh P, Mamdani M, Juurlink D, Gomes T. Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. *Int J Technol Assess Health Care*. 2020;36(1):12-19. **Principal Author**
160. Hayes KN, Nakhla NR, **Tadrous M**. Further Evidence to Monitor Long-term Proton Pump Inhibitor Use. *JAMA Network Open*. 2019 Nov 1;2(11):e1916184. **Senior Responsible Author**
161. Choremis B, Campbell T, **Tadrous M**, Martins D, Antoniou T, Gomes T. The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. *PLoS one*. 2019;14(10). **Coauthor**

162. Mamdani M, Gomes T, Greaves S, Manji S, Juurlink DN, **Tadrous M**, Kennedy SH, Antoniou T. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. *JAMA Network Open*. 2019 Oct;2(10). **Coauthor**
163. Iaboni A, Campitelli MA, Bronskill SE, Diong C, Kumar M, Maclagan LC, Gomes T, **Tadrous M**, Maxwell CJ. Time Trends in Opioid Prescribing among Ontario Long-Term Care Residents: A Repeated Cross-Sectional Study. *CMAJ Open* 7, no. 3 (Jul-Sep 2019): E582-e89. **Coauthor**
164. Wong WW, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, **Tadrous M**, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn M (2019). Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. *Systematic Reviews* 8(1): 207. **Coauthor**
165. Schumock GT, Stubbings J, Hoffman JM, Wiest MD, Suda JK, Rim MH, **Tadrous M**, Tichy EM, Cuellar S, Clark JS, Matusiak LM, Hunkler R, Vermeulen LC. National trends in prescription drug expenditures and projections for 2019. *American Journal of Health-System Pharmacy*. **Coauthor**
166. Gomes T, Khuu W, **Tadrous M**, Vigod S, Cobigo V, Lunsky Y. Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. *BMJ Open* 2019;9:e028125. doi: 10.1136/bmjopen-2018-028125 **Coauthor**
167. **Tadrous M**, Matta R, Greaves S, Herschorn S, Mamdani MM, Juurlink DN, Gomes T. Association of mirabegron with the risk of arrhythmia in adult patients 66 years or older—a population-based cohort study. *JAMA Internal Medicine*. 2019;179(10):1436-9. **Principal Author**
168. Soobiah C, **Tadrous M**, Knowles S, Blondal E, Ashoor H, Ghassemi M, Khan PA, Ho J, Tricco AC, Straus SE. Variability in the Validity and Reliability of Outcome Measures Identified in a Systematic Review to Assess Treatment Efficacy of Cognitive Enhancers for Alzheimer's Dementia. *PLOS ONE*. 2019 April 18. **Coauthor**
169. Martins D, Khuu W, **Tadrous M**, Juurlink DN, Mamdani MM, Paterson JM, Gomes T. Impact of Delisting High-Strength Opioid Formulations from a Public Drug Benefit Formulary on Opioid Utilization in Ontario, Canada. *Pharmacoepidemiology and Drug Safety*. 2019 March 14. **Coauthor**
170. **Tadrous M**, S. Greaves, D. Martins, K. Nadeem, S. Singh, M. M. Mamdani, D. N. Juurlink and T. Gomes. Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. *International Journal of Drug Policy*. 2019 April. 66: 82-86. **Principal Author**
171. Antoniou T, Ala-Leppilamp K, Shearer D, Parson JA, **Tadrous M**, Gomes T. “Like being put on an ice floe and shoved away”: A qualitative study of the impacts of opioid-related policy changes on people who take opioids. *IJDP*. 2019 January 24. **Coauthor**
172. **Tadrous M**. Opioids in Ontario: The current state of affairs and a path forward. *Expert Review of Clinical Pharmacology- E-Pub* August 2018. **Principal Author**
173. Yu X, Gomes T, Mamdani MM, Cadarette SM, Juurlink DN, **Tadrous M**, Analysis of Trends in Insulin Utilization and Spending in Adults and Children with Insulin-dependent Diabetes Across Canada from 2010 to 2015. *Canadian Journal of Diabetes– E-Pub*. **Senior Responsible Author**
174. Parkin L, Khuu W, Stanbrook MB, **Tadrous M**, Martins D, Gomes T. Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: a

Mina TADROUS

population-based study. Respiratory Medicine– E-Pub. **Coauthor**

175. Gomes T, Khuu W, Martins D, **Tadrous M**, Mamdani MM, Paterson JM, Juurlink DN. Contributions of prescribed and non-prescribed opioids to opioid-related deaths: A population-based cohort study in Ontario, Canada. The BMJ. 2018 August 29. **Coauthor**
176. Gomes T, Khuu W, Craiovan D, Martins D, Hunt J, Lee K, **Tadrous M**, Mamdani MM, Paterson JM, Juurlink DN. Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: a multi-jurisdictional cross-sectional study. Drug & Alcohol Dependence – E-Pub. **Coauthor**
177. Ban J, **Tadrous M**, Cicinelli E, Lu A, Cadarette S. History and Publication Trends in the Diffusion and Early Uptake of Indirect Comparison Meta-Analytic Methods to Study Drugs: Animated Co-Authorship Networks over Time. BMJ OPEN. **Coauthor**
178. Verma AA, Khuu W, **Tadrous M**, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLOS Medicine. **Coauthor**
179. Xu Y, Amiche MA, **Tadrous M**. Network Meta-analysis: An Introduction for Pharmacists. International Journal of Clinical Pharmacy. **Senior Responsible Author**
180. Antoniou T, Macdonald EM, Yao Z, Gomes T, **Tadrous M**, Ho J, Mamdani MM, Juurlink DN. A Population-Based Study of the Risk of Osteoporosis and Fracture with Dutasteride and Finasteride. BMC Musculoskeletal Disorders- E-Pub. **Coauthor**
181. **Tadrous M**, Brahmania M, Martins D, Knowles S, Janssen HLA, Mamdani MM, Juurlink DN, Gomes T. Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over Sixteen Years: an Ecologic Study. J Manag Care Spec Pharm. 2018 May;24(5). **Principal Author**
182. Spithoff S, Kiran T, Khuu W, Kahan M, Guan Q, **Tadrous M**, Leece P, Martins D, Gomes T. Quality of primary care among individuals receiving treatment for opioid use disorder. Canadian Family Physicians. April 2018. **Coauthor**
183. Pasricha S, **Tadrous M**, Khuu W, Juurlink D, Mamdani M, Paterson M, Gomes T. Clinical indications associated with opioid initiation for pain management in Ontario, Canada: A population-based cohort study. PAIN. Accepted- April 2018. **Coauthor**
184. Gomes T, **Tadrous M**, Mamdani MM Paterson JM, Juurlink DN. The Burden of Opioid-Related Mortality in the United States. JAMA Network Open. Accepted- March 2018. **Coauthor**
185. Guan Q, Khuu W, Martins D, **Tadrous M**, Chiu M, Do M, Gomes T. Evaluating the Early Impacts of Delisting of High Strength Opioids on Patterns of Prescribing in Ontario. Health Promotion and Chronic Disease Prevention in Canada. Accepted – March 2018. **Coauthor**
186. Gomes T, Greaves S, **Tadrous M**, Mamdani MM Paterson JM, Juurlink DN. Measuring the Burden of Opioid-Related Mortality in Ontario, Canada. Journal of Addiction Medicine. Accepted- February 2018. **Coauthor**
187. Borgundvaag B, McLeod S, Khuu W, Varner C, **Tadrous M**, Gomes T. Comparing opioid prescribing and adverse events for opioid naive patients treated by emergency versus family physicians: a population- based cohort study. CMAJ open, 6(1), E110. **Coauthor**

188. Black CD, McCarthy L, Gomes T, Mamdani MM, Juurlink DN, **Tadrous M**. Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. Accepted -Canadian Geriatrics Journal February 2018. **Senior Responsible Author**
189. **Tadrous M**, Greaves S, Martins D, Mamdani MM, Juurlink DN, Gomes T. Catastrophic Drug Coverage: Utilization from the Ontario Trillium Drug Program. CMAJ open, 6(1), E132. **Principal Author**
190. Minhas R, **Tadrous M**, Elterman D, Gomes T. Trends in the Use of Older Overactive Bladder Agents and Uptake of Fesoterodine and Mirabegron in Canada. Neurourology and Urodynamics. **Coauthor**
191. Gao L, **Tadrous M**, Knowles S, Mamdani MM, Paterson JM, Juurlink DN, Gomes T. Prior Authorization and Canadian Public Utilization of Direct-acting Oral Anticoagulants. Healthcare Policy. **Coauthor**
192. **Tadrous M**, Khuu W, Lebovic G, Stanbrook M, Martins D, Paterson JM, Mamdani M, Juurlink DN, Gomes T. Real-world effectiveness of omalizumab for the treatment of severe asthma. Annals of Allergy, Asthma & Immunology 120.1 (2018): 59-65. **Principal Author**
193. Lunskey Y, Khuu W, **Tadrous M**, Vigod S, Cobigo V, Gomes T. Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. The Canadian Journal of Psychiatry (2017): 0706743717727240. **Coauthor**
194. Guan Q, Khuu W, Spithoff S, Kiran T, Kahan M, **Tadrous M**, Leece P, Martins D, Gomes T. Patterns of Physician Prescribing for Opioid Maintenance Treatment in Ontario, Canada in 2014. Drug and alcohol dependence, 177, 315-321. **Coauthor**
195. **Tadrous M**, Khuu W, Elterman D, Martins D, Juurlink DN, Paterson JM, Mamdani MM, Gomes T. Publicly Funded Overactive Bladder Drug Treatment Patterns in Ontario over Fifteen Years: an Ecologic Study. Canadian Urological Association Journal. Canadian Urological Association Journal, 12(3), E142. **Principal Author**
196. Kwok H, Khuu W, Fernandes K, Martins D, **Tadrous M**, Singh S, Juurlink DN, Gomes T. Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. Pain Med. 2017 Jun 1;18(6):1019-1026. **Coauthor**
197. Cadarette SM, Ban JK, Consiglio GP, Black CD, Marin A, Dubins D, **Tadrous M**. Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice. Journal of Clinical Epidemiology. 2017 Apr;84:150-160. **Senior Responsible Author**
198. Antoniou T, Macdonald EM, Yao Z, Hollands S, Gomes T, **Tadrous M**, Mamdani MM, Juurlink DN. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. Canadian Medical Association Journal. 2017 Jan 9; 189(1):E4-10. **Coauthor**
199. Gomes T, Martins D, **Tadrous M**, Paterson JM, Shah BR, Tu JV, Juurlink DN, Chu A, Mamdani MM. Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes: A Population-Based Study. JAMA Internal Medicine. 2017 Jan 1;177(1):61-66. **Coauthor**
200. **Tadrous M**, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. Varenicline and Risk of Self-Harm: A Nested Case-Control Study. PloS one. 2016 Sep 23; 11(9):e0163681. **Principal Author**

Mina TADROUS

201. Martins, D., Yao, Z., **Tadrous, M.**, Shah, B.R., Juurlink, D.N., Mamdani, M.M., Gomes, T. and Ontario Drug Policy Research Network, 2017. The appropriateness and persistence of testosterone replacement therapy in Ontario. *Pharmacoepidemiology and drug safety*, 26(2), pp.119-126. **Coauthor**
202. Mast G, Fernandes K, **Tadrous M**, Martins D, Herrmann N, Gomes T: Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. *Drugs-Real World Outcomes* 2016:1-8. **Coauthor**
203. Arora N, Knowles S, Gomes T, Mamdani MM, Juurlink DN, Carlisle C, **Tadrous M**. Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. *The Canadian Journal of Psychiatry* 2016. **Senior Responsible Author**
204. **Tadrous M**, Khuu W, Paterson JM, Mamdani MM, Juurlink DN, Gomes T: Off-label use of inhaled tobramycin in Ontario, Canada. *Thorax* 2016. **Principal Author**
205. Gomes T, Martins D, **Tadrous M**, Paterson JM, Shah BR, Juurlink DN, Singh S, Mamdani MM: Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. *Canadian journal of diabetes* 2016. **Coauthor**
206. Desveaux L, Gomes, T, **Tadrous, M**, Jeffs, Taljaard, M, Rogers, J., Ivers, N. M. Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. *Implementation Science* 2016; **11**(1):1-10. **Coauthor**
207. **Tadrous M**, Martins D, Lee K, Knowles S, Mamdani MM, Juurlink DN, Gomes T. Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. *Expert review of pharmacoeconomics & outcomes research*. 2016 Nov 1;16(6):803-7. **Principal Author**
208. Amiche MA, Albaum JM, **Tadrous M**, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. *Osteoporosis International*. 2016 Jun 1;27(6):1989-98. **Coauthor**
209. Amiche MA, Albaum JM, **Tadrous M**, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM. Fracture risk in oral glucocorticoid users: a Bayesian meta-analysis leveraging control arms of osteoporosis clinical trials. 2015. *Osteoporosis International*. **Coauthor**
210. Fraser L-A, Albaum JM, **Tadrous M**, Burden AM, Shariff SZ, Cadarette SM. Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. *Canadian Medical Association Open Access Journal*. 2015; 3(1):E91-E96. **Coauthor**
211. **Tadrous M**, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM. Performance of the disease risk score in a cohort study with policy-induced selection bias. *Journal of comparative effectiveness research*. 2015; 4(6):607-614. **Coauthor**
212. Burden A, **Tadrous M**, Calzavara A, Cadarette S. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. *Osteoporosis International*. 2015:1-9. **Coauthor**
213. Wong L, Burden AM, Liu YY, **Tadrous, M.**, Pojskic, N., Dolovich, L, Cadarette, S. M. (2015). Initial uptake of the Ontario Pharmacy Smoking Cessation Program Descriptive analysis over 2 years.

Mina TADROUS

Canadian Pharmacists Journal. 148(1), 29-40. **Coauthor**

214. Greiss J, **Tadrous M**. Proceed with caution: The possible impact of preferred-provider networks. Canadian Pharmacists Journal. 2014; 147(5):273-274. **Senior Responsible Author**
215. **Tadrous M**, Wong L, Juurlink DN, Krahn M, Lévesque LE, Mamdani MM, Cadarette SM. Comparative Gastrointestinal Safety of Bisphosphonates in Primary Osteoporosis: A Network Meta-Analysis. Osteoporos Int. Apr 2014; 25(4):1225-1235. **Principal Author**
216. Cadarette SM, Levesque L, Mamdani M, Perreault S, Juurlink D, Paterson M, Carney G, Gunraj N, Hawker G, **Tadrous M**, Wong L, Dormuth C. Comparative Effectiveness of Oral Bisphosphonates in Reducing Hip Fracture Risk in Older Men and Women: Population-based Cohort Study. CMAJOpen-Open Access. **Coauthor**
217. Burden, AM, Huang A, **Tadrous M**, Cadarette SM. Variation in the days supply field for osteoporosis medications in Ontario. Arch Osteoporos; 2013; 8: 128. **Coauthor**
218. **Tadrous M**, Gagne JJ, Sturmer T, Cadarette SM. Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations. Pharmacoepidemiology and Drug Safety – 2013 Feb;22(2). **Principal Author**
219. Rofail P, Tadros M, Ywakim R, **Tadrous M**, Krug A, Cosler LE. Pegfilgrastim: A Review of the Pharmacoeconomics for Chemotherapy. Expert Review of Pharmacoeconomics and Outcomes Research 2012 Dec; 12(6) 699-709. **Coauthor**
220. Gharbawy DE, **Tadrous M**, Suda KJ. Does depression lead to influenza? – A systematic literature analysis. Journal of Affective Disorders. 2012 Apr; 138 (1) 41-45. **Coauthor**
221. **Tadrous M**, Gharbawy DE, Hurley A, Miller B, Suda KJ. “Establishing a Complete Drug Information Triad: Academic, Industry, and Hospital Training.” Drug Information Journal 2011; 45(1); 641-644. **Principal Author**
222. Meek PD, Evang S, **Tadrous M**, Triller D. Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo Controlled Trials. Digestive Disease Science 2011; 56(1); 7-18. **Coauthor**
223. Hurley AM, **Tadrous M**, Miller ES. Thimerosal-containing vaccines and autism: a review of epidemiologic studies. J Pediatr Pharmacol Ther. 2010 Jul-Sep; 15(3); 173-181. **Coauthor**
224. Triller DM, Evang SD, **Tadrous M**, Yoo BK. First renin inhibitor, aliskiren, for the treatment of hypertension. Pharmacy World Science 2008; 30:741-9. **Coauthor**
225. Levin RM, Whitbeck C, Sourial MW, **Tadrous M**, Millington WR. Effects of dextromethorphan on in vitro contractile responses of mouse and rat urinary bladders. Neurorol Urodyn. 2006; 25(7):802-807. **Coauthor**

Book Chapters

1. Crill CM, American Society of Health-System Pharmacists, Hak EB, Phelps SJ. Teddy bear book: pediatric injectable drugs. 9th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2009. **Contributing author**

Mina TADROUS

2. Gourley DR, Eoff JC. American Pharmacist Association. The APhA Complete Review for Pharmacy, 7th Edition; 2010. **Contributing author**
3. Gourley DR, Eoff JC. American Pharmacist Association. The APhA Complete Review for Pharmacy, 8th Edition 2012; **Contributing author**
4. Gourley DR, Eoff JC. American Pharmacist Association. The APhA Complete Review for Pharmacy, 9th Edition 2013; **Contributing author**

Public Reports and Reviews

1. **Tadrous M**, Hurley AM. "Changing health outcomes through beliefs and knowledge: examples learned from osteoporosis"- Tennessee Pharmacist. Summer 2009
2. **Tadrous M**, Hoffman J. "Oral Syringes Vs. IV Syringes"- St. Jude Children's Research Hospital. Parents Newsletter. July 2009
3. **Tadrous M**. New FDA Approvals 2009 - January through March. Tennessee Pharmacist – Winter 2010
4. Cadarette SM, Wong LW, **Tadrous M**. "Oral Bisphosphonates - The "bone" fide truth about their use in osteoporosis"- Pharmacy Practice- Invited Review. September 2013
5. Martins, D., Stanbrook, M., Fernandes, K., Yao, Z., Singh, S., **Tadrous, M**, Mamdani MM, Juurlink DN, Gomes, T. (2014). Inhaled Corticosteroids (ICS) + Long-Acting Beta-Agonists (LABA) for treatment of asthma. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
6. **Tadrous M**, Martins D, Herrmann N, Fernandes, K., Yao, Z., Singh, S, Mamdani MM, Juurlink DN, Gomes, T. Antipsychotics in the Elderly. 2015. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
7. Gomes, T., Martins, D., Singh, S., Mamdani, M., Dhalla, I., Paterson, M., **Tadrous M**, Juurlink, D. Opioid Related Deaths in Ontario Between 1991 and 2010. September 2014- ODPRN Report.
8. Martins D, Fernandes K, Yao Z, Singh S, Shah B, Knowles S, Juurlink D, Mamdani M, **Tadrous M**, Gomes T. Testosterone replacement therapy: Pharmacoepidemiology Unit. December 2014.
9. Gomes T, Juurlink D, Mamdani M, Martins D, Paterson M, Singh S, **Tadrous M**, Yao Z. (2015). Concurrent use of short acting beta-agonists and ipratropium in Ontario. Report to the Ontario Ministry of Health.
10. Gomes T, Juurlink D, Mamdani M, Martins D, Paterson M, Shah B, Singh S, **Tadrous M**. Evaluation of Ontario SMBG Reimbursement Policy. Part 1: Impact on Utilization Trends (2015). Report to the Ontario Ministry of Health
11. **Tadrous M**, Khuu W, Singh S, Juurlink D, Mamdani M, Paterson M, Gomes T. UPDATE: Use of Inhaled Tobramycin in Cystic Fibrosis Patients (2015). Report to the Ontario Ministry of Health
12. Gomes T, Knowles S, **Tadrous M**, Martins D, Mast G, Spithoff S. (2015). Drugs for Alcohol Use Disorders. Report to the Ontario Ministry of Health
13. Gomes T, Juurlink DN, Khuu W, Martins D, Paterson JM, Singh S, **Tadrous M**, Mamdani MM. (2015). Trends in use of denosumab in Ontario. Report to the Ontario Ministry of Health

Mina TADROUS

14. **Tadrous M**, Khuu W, Knowles S, Fernandes K, Martins D, Singh S, Paterson JM, Juurlink DN, Mamdani MM, Gomes T. (2015). Pregabalin Use in Ontario. Report to the Ontario Ministry of Health
15. **Tadrous M**, Martins D, Herrmann N, Fernandes K, Yao Z, Singh S, Paterson M, Juurlink D, Mamdani M, Gomes T. Antipsychotics in the Elderly: Pharmacoepidemiology Report. May 2015.
16. Martins D., **Tadrous M**, Fernandes K, Yao Z, Singh, S., Knowles S, Juurlink, D, Paterson, M., Mamdani M, Gomes, T. Treatment of Chronic Hepatitis B in Ontario. November 2015. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
17. **Tadrous M**, Martins D., Yao Z, Fernandes K, Singh, S., Arora N, Juurlink, DN, Mamdani M, Gomes, T (2015). Cognitive Enhancers. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
18. Martins D., Khuu W, **Tadrous M**, Yao Z, Spooner LW, Singh, S, Fernandes K, Knowles S, Juurlink DN, Paterson, M., Mamdani M, Gomes, T. Treatments for ADHD in Adults. October 2015. Pharmacoepidemiology Report (ODPRN Drug Class Reviews).
19. Gomes T, Fernandes K, Paterson JM, Martins D, Singh S, **Tadrous M**, Mamdani MM, Juurlink DN. Opioid prescribing and opioid-related hospital visits in Ontario. July 2015.
20. Gomes T, Martins D, Fernandes K, Singh S, **Tadrous M**, Arora N, Juurlink DN, Paterson JM, Mamdani MM. Allergen Immunotherapy Products: Final Pharmacoepidemiology Report. September 2015. Pharmacoepidemiology Report (ODPRN Drug Class Reviews).
21. Gomes T, **Tadrous M**, Knowles S, Martins D, Singh S, Paterson M, Juurlink D, Mamdani M. Potential Options for a Designated Prescribing List of Medications for Registered Nurses in Ontario (2016). Report to Nursing Policy and Innovation Branch, Ontario Ministry of Health and Long Term Care.
22. **Tadrous M**, Greaves S, Granton J, Khuu W, Martins D, Singh S, Juurlink D, Mamdani M, Gomes T. (2016). Patterns of drug therapy use for pulmonary arterial hypertension (PAH) in Ontario. Report to the Ontario Ministry of Health
23. **Tadrous M**, Khuu W, Elterman D, Singh S, Fernandes K, Martins D, Juurlink DN, Paterson JM, Mamdani MM, Gomes T. Treatment for Overactive Bladder: Pharmacoepidemiology report. March 2016. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
24. Martins D, Khuu W, **Tadrous M**, Singh S, Carrier M, Juurlink DN, Paterson JM, Mamdani MM, Gomes T. Low Molecular Weight Heparins: Pharmacoepidemiology report. April 2016. Pharmacoepidemiology Report (ODPRN Drug Class Reviews)
25. Guan Qi, Khuu W, Spithoff S, Kiran T, Kahan M, **Tadrous M**, Martins D, Leece P, Gomes T. Clustering of methadone and buprenorphine prescribing in Ontario in 2014. April 2016. Report to the Ontario Ministry of Health
26. Gomes T, Khuu W, **Tadrous M**, Singh S, Mamdani MM, Juurlink DN. High strength opioid formulations in Ontario: by the numbers. August 2, 2016.
27. Martins D, Greaves S, **Tadrous M**, Paterson JM, Bandola D, Singh S, Juurlink DN, Mamdani MM, Gomes T. Opioid use and related adverse events in Ontario. November 2016

Mina TADROUS

28. **Tadrous M**, Khuu W, Martins D, Juurlink DN, Mamdani MM, Gomes T. (2017). Delisting of high strength opioid formulations: An Evaluation. Part 1. Ontario Drug Policy Research Network. Report to the Ontario Ministry of Health
29. Martins D, Greaves S, **Tadrous M**, Singh S, Paterson M, Juurlink D, Mamdani M, Gomes T. (2017). Patterns of methylphenidate extended release use in Ontario. Report #2. 15. Report to the Ontario Ministry of Health
30. **Tadrous M**, Greaves S, Martins D, Singh S, Juurlink DN, Mamdani MM, Gomes T. (2017). Use and patient characteristics of the Ontario Trillium Program. Ontario Drug Policy Research Network. Report to the Ontario Ministry of Health
31. Gomes T, Martins D, **Tadrous M**, Paterson JM, Juurlink DN, Mamdani MM. (2017). MedsCheck Use in Ontario: An updated analysis. 12. Report to the Ontario Ministry of Health
32. Gomes T, Greaves S, Martins D, Bandola D, **Tadrous M**, Singh S, Juurlink D, Mamdani M, Paterson M, Ebejer T, May D, Quercia J. Latest trends in opioid-related deaths in Ontario: 1991 to 2015: exploring differences among men and women. Toronto: Ontario Drug Policy Research Network; May 2017.
33. Gomes T, **Tadrous M**, Greaves S, Mamdani MM. (2017). High Drug-Cost Beneficiaries of the Ontario Public Drugs Programs (OPDP): Part 1. Report to the Ontario Ministry of Health
34. **Tadrous M**, Greaves S, Martins D, Singh S, Paterson M, Juurlink D, Mamdani M, Gomes T. (2017). High drug cost beneficiaries of the Ontario Public Drug Programs. Part 2. Report to the Ontario Ministry of Health
35. **Tadrous M**, Gomes T. (2017). Brand versus generic Concerta adherence: A critical appraisal.
36. Gomes T, Pasricha S, Martins D, Greaves S, **Tadrous M**, Bandola D, Singh S, Paterson JM, Mamdani MM, Juurlink DN. Behind the Prescription: A Snapshot of Opioid Use across Ontario. August 2017
37. Martins D, Greaves S, **Tadrous M**, Bandola D, et al on behalf of the ODPRN Citizens' Panel. Landscape of Prescription Stimulant Use: Patterns, Trends and Geographic Variation in Ontario, Canada. Toronto: Ontario Drug Policy Research Network; September 2018.
38. Coyle D, Martins D, **Tadrous M**, Mamdani M, Singh S, Gomes T. Triptans for migraine therapy budget impact analysis. (2018). A Report to the Ontario Ministry of Health.
39. Martins D, **Tadrous M**, Campbell T, Choremis B, Antoniou T, Singh S, Gomes T. Uptake of pharmacy dispensed naloxone in Ontario. (2018). A Report to the Ontario Ministry of Health.
- 1.
40. Martins D, Khuu W, **Tadrous M**, Singh S, Mamdani M, Gomes T. Low-Emetogenic Chemotherapy Regimens (2018). Report to the Ontario Ministry of Health
41. Martins D, Campbell T, **Tadrous M**, Singh S, Mamdani M, Gomes T. Levetiracetam (Keppra) Use in Ontario (2018). Report to the Ontario Ministry of Health
42. **Tadrous M**, Khuu W, Martins D, Singh S, Mamdani M, Gomes T. Utilization of Benzotropine in Ontario (2018). Report to the Ontario Ministry of Health
43. **Tadrous M**, Greaves S, Martins D, Gomes T. Forecasts of Patterns in High Drug-Costs Beneficiaries of the Ontario Public Drugs Program (2018). Report to the Ontario Ministry of Health

44. Gomes T, **Tadrous M**, McCormack D, Martins D, Mamdani M, Paterson M. Measuring the potential impact of changing biosimilar policies for rheumatic conditions and IBD. (2019). Report to the Ontario Ministry of Health.
45. Martins D, McCormack D, **Tadrous M**, Singh S, Gomes T. Concomitant use of dabigatran and proton pump inhibitors. (2019). Report to the Ontario Ministry of Health.
46. Martins D, Khuu W, Greaves S, **Tadrous M**, Sprole B, Bozinoff N, Juurlink D, Paterson M, Mamdani M, Gomes T. Prevalence of potential rapid tapering of opioid doses in Ontario, Canada. (2019). Report to the Ontario Ministry of Health.
47. Martins D, McCormack D, **Tadrous M**, Paterson M, Singh Samantha, Gomes T. Prevalence of hospital visits with blood product use among individuals not eligible for the Ontario Health Insurance Plan (2019). Report to the Ontario Ministry of Health
48. **Tadrous M**, Shearer D, Martins D, Campbell T, Gomes T. Naloxone Distribution Across Ontario. Toronto: Ontario Drug Policy Research Network; June 2019.
49. **Tadrous M**. Ontario Agency for Health Protection and Promotion (Public Health Ontario); Office of the Chief Coroner; Ontario Forensic Pathology Service; Ontario Drug Policy Research Network. Opioid mortality surveillance report: analysis of opioid-related deaths in Ontario July 2017-June 2018. Toronto, ON: Queen's Printer for Ontario; 2019.
50. **Tadrous M**. Ontario Drug Policy Research Network; Office of the Chief Coroner for Ontario/Ontario Forensic Pathology Service; Ontario Agency for Health Protection and Promotion (Public Health Ontario); Centre on Drug Policy Evaluation. Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. Toronto, ON: Ontario Drug Policy Research Network; 2020. <https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en>
51. **Tadrous M**, McCormack D, Martins D, Kitchen S, Singh S, Gomes T. Current and prospective utilization of innovator biologics and biosimilars in Ontario; January 2020. Available at: <https://odprn.ca/wp-content/uploads/2020/01/Utilization-of-Innovator-Biologics-and-Biosimilars-in-Ontario.pdf>
52. Martins D, Men S, **Tadrous M**, Gomes T. Immunosuppressant Use among People with Crohn's Disease and Ulcerative Colitis. (2020). Report to the Ontario Ministry of Health
53. **Tadrous M**, McCormack D, Gomes T. Pharmacist Prescribing of Controlled Substances Following COVID-19 Exemptions. (2020). Report to the Ontario Ministry of Health
54. **Tadrous M**, McCormack D, Martins D, Singh S, Gomes T. Regional Access to Services among Individuals with Hepatitis C in Ontario. Report to the Hepatitis C Secretariat at the Ontario Ministry of Health.
55. **Tadrous M**, Gomes T. Adjudication processes by pharmacies in Primarily English-Speaking Jurisdictions with a Focus on the Public Payer: An Environmental Scan. (2021). Report to the Ontario Ministry of Health.
56. Kitchen S, Men S, Campbell T, **Tadrous M**, Gomes T. Limited Use Criteria for Heterozygous Familial Hypercholesterolemia. (2021). Report to the Ontario Ministry of Health.
57. Campbell T, Men S, Brar G, Singh S, Antoniou T, **Tadrous M**, Gomes T, Ebejer T, Joosse M, Quercia J, Sanders J. Characterizing prescription benzodiazepine use among community-dwelling residents of

Ontario, Canada. (2021). Available at: <https://odprn.ca/research/publications/prescription-benzodiazepine-use-in-ontario/>

58. Harris DA, Guo Y, Nakhla N, **Tadrous M**, Hogan DB, Hennessy D, Langlois K, Garner R, Leslie S, Bronskill SE, Heckman G, Maxwell CJ. "Prevalence of prescription and non-prescription polypharmacy by frailty and sex among middle-aged and older Canadians"- Statistics Canada. June 2022. doi:10.25318/82-003-x202200600001-eng
59. "Everyone sees me as super successful but I've been struggling for years". What we heard at the Town Hall on access to treatment and services for ADHD into adulthood. October 28, 2022. <https://odprn.ca/wp-content/uploads/2022/10/ADHD-Town-Hall-Report.pdf>
60. Guan Q, Garg R, Lunsky Y, **Tadrous M**, McCormack D, Gomes T. Impact of the COVID-19 pandemic on use of medication and healthcare services among individuals with intellectual and developmental disabilities in Ontario. (2023). Report to the Ontario Ministry of Health.

4. NON-PEER-REVIEWED PUBLICATIONS

Selected Abstracts

1. Kim KC, Rothenberger SD, **Tadrous M**, Hernandez I, Gellad W, Maillart L, Suda KJ. Impact of the COVID-19 Pandemic on the Incidence of Drug Shortages in the United States. Academy Health Annual Research Meeting. Seattle, Washington. Poster Presentation. June 2023
2. Schwartz KL, Wang J, **Tadrous M**, Langford BJ, Daneman N, Leung V, Gomes T, Friedman L, Daley P, Brown KA. Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada. medRxiv BMJ. 2022 Nov 5. doi:10.1101/2022.11.03.22281881.
3. Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, Brown KA, Fell DB, Gubbay J, Schwartz KL, **Tadrous M**, Wilson K, Kwong JC. Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. medRxiv BMJ. 2022 Nov 1. doi: <https://doi.org/10.1101/2022.10.31.22281766>.
4. Garg R, Kitchen SA, Men S, Campbell TJ, Bozinoff N, **Tadrous M**, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis. Canadian Association for Population Therapeutics Conference. Poster Presentation. October 2022.
5. Chaudhry S, Chang A, McCormack D, Gomes T, Shivji A, **Tadrous M**. Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis. Canadian Association for Population Therapeutics Conference. Poster Presentation. October 2022.
6. Yang A, Alabaku O, Tharmarajah S, Suda KJ, Vigod SN, **Tadrous M**. Global Trends in Antidepressant, Atypical Antipsychotic, and Benzodiazepine Use: A cross-sectional analysis of 64 countries. Canadian Association for Population Therapeutics Conference. Poster Presentation. October 2022.
7. Quanbury A, Hart D, Lexchin J, **Tadrous M**, Gagnon MA, Grundy Q. Mapping the extent, nature, and range of pharmaceutical industry patient support programs in Canada. Canadian Association for Population Therapeutics Conference. Poster Presentation. October 2022.

Mina TADROUS

8. Choi Y, Santhireswaran A, Chu C, Suda KJ, Hernandez I, Magnani JW, **Tadrous M**. Global Extent of the Valsartan Drug Recall and its Effect on Antihypertensive Drug Use: a Multi-National Study. Canadian Association for Population Therapeutics Conference. October 2022.
9. Santhireswaran A, Chu C, **Tadrous M**. Tier 3 Drug Shortages and their Effects on Utilization Trends in Canada. Canadian Association for Population Therapeutics Conference. Poster Presentation. October 2022.
10. Stamenova V, Chu C, Borgundvaag E, Fleury C, Brual J, Bhattacharyya O, **Tadrous M**. Virtual care use prior to emergency department admissions during a stable COVID-19 period in Ontario, Canada. medRxiv BMJ. 2022 Oct 21. doi: <https://doi.org/10.1101/2022.10.20.22281298>
11. Hernandez I, He M, Guo J, **Tadrous M**, Gabriel N, Swabe G, Gellad WF, Essien U, Saba S, Benjamin E, Magnani J. COVID-19 Pandemic and Trends in New Diagnosis of Atrial Fibrillation. Academy Health 2022 Annual Research Meeting. Washington, DC. Poster Presentation. 5 Jun 2022.
12. Savoie-White FH, Tremblay L, Menier CA, Duval C, Bergeron F, **Tadrous M**, Guertin JR, Ugalde PA. L'utilisation précoce des bloqueurs neuromusculaires dans le syndrome de détresse respiratoire aiguë. Oral presentation to the 89e Congrès de l'Acfas. ACFAS Virtual Conference. Oral Presentation. 9-13 May 2022.
13. Stamenova V, Chu C, Pang A, Fang J, Shakeri A, Cram P, Bhattacharyya O, Bhatia S. **Tadrous M**. Virtual care use during the COVID-19 pandemic and its impact on healthcare utilization in patients with chronic disease: a population-based repeated cross-sectional study. CAHSPR, Virtual Conference. Poster Presentation. 9-13 May 2022.
14. Stamenova V, Chu C, Brual J, Fleury C, Fang J, Bhatia S, **Tadrous M**. Virtual care use during waves of the COVID-19 pandemic in Ontario: a retrospective cohort study. CAHSPR, Virtual Conference. Poster Presentation. 9-13 May 2022.
15. Campbell T, Joesse M, Men S, Singh S, **Tadrous M**, Antoniou T, Ebejer T, Sanders J, Quercia J, Gomes T. Creating Impact Through Citizen-Led Research: Engaging the Ontario Drug Policy Research Network Citizens' Panel in Characterizing Prescription Benzodiazepine Use in Ontario. 2021 CADTH Symposium, Virtual Conference. Poster Presentation. November 2021
16. Callaway Kim K, **Tadrous M**, Kane-Gill SL, Barbash IJ, Rothenberger S, Suda KJ. Changes in Purchases for Intensive Care Medicines in Developed vs. Developing Countries. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Virtual Conference, August 2021.
17. Tourchian N, **Tadrous M**. Opioid agonist therapy as treatment for opioid use disorder: Comparing duration, risks and frequency of healthcare encounters. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Poster Presentation. Oct 2020.
18. **Tadrous M**, McCormack D, Kitchen S, Diana M, Gomes T. The impact of changing biosimilar policies for rheumatic conditions and inflammatory bowel disease in Ontario, Canada. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Poster Presentation. Oct 2020.
19. **Tadrous M**, Mason K, Lettner B, Guyton M, Dodd Z, Powis J, Martins D, Gomes T. Prescribing trends of direct acting antivirals for the treatment of hepatitis C in Ontario. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Poster Presentation. Oct 2020.

Mina TADROUS

20. Chen TC, Wettermark B, Steinke D, Caughey G, **Tadrous M**, Wirtz V, Chen LC. Assessing the feasibility of leveraging healthcare databases to conduct cross-national comparisons of opioid utilisation. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Poster Presentation. Oct 2020.
21. Williams E, **Tadrous M**, Maxwell C, Nakhla N. A Canadian research agenda for non-prescription products and care of vulnerable older adults by community pharmacists. Can Pharm J (Ott). 2020;153(6):S75. Available online. 2020 CPERC Conference. Poster Presentation. Jun 2020 (cancelled).
22. Williams E, **Tadrous M**, Maxwell C, Nakhla N. Assessing the feasibility and acceptability of frailty detection by community pharmacists. Can Pharm J (Ott). 2020;153(6):S74. Available online. Abstract selected for poster presentation at 2020 CPERC Conference. Poster Presentation. Jun 2020 (cancelled).
23. **Tadrous M**, Suda K, Gomes T. "Impact of two recent major drug shortages on drug utilization." Pharmacoepidemiology and Drug Safety. Poster Presentation. vol. 29, pp. 156-157; 2020.
24. Campbell T, Martins D, **Tadrous M**, Juurlink D, Paterson JM, Mamdani M, Mock D, Gomes T. "The association between dental opioid prescription characteristics and the risk of long-term use and overdose." Pharmacoepidemiology and Drug Safety. Oral Presentation. vol. 29, pp. 171-172; 2020.
25. Hincapie-Castillo JM, Goodin AJ, Dal Pan GJ, **Tadrous M**. "Methods to evaluate the effects of policy changes during the opioid crisis." Pharmacoepidemiology and Drug Safety. Oral Presentation. vol. 29, pp. 153-154; October 2020.
26. Teng-Chou C, Wettermark B, Steinke D, Caughey G, **Tadrous M**, Wirtz V, Chen LC. "Comparing opioid regulations globally across regions with different levels of opioid utilisation." Pharmacoepidemiology and Drug Safety. Oral Presentation. vol. 29, pp. 165-165; 2020.
27. **Tadrous M**, McCormack D, Kitchen S, Diana M, Gomes, T. The impact of changing biosimilar policies for rheumatic conditions and inflammatory bowel disease in Ontario, Canada. Pharmacoepidemiology and Drug Safety. Philadelphia, PA. Poster Presentation. Aug 2019.
28. **Tadrous M**, Martins D, Choremis B, Campbell T, Antoniou T, Gomes T. Uptake of the Ontario naloxone program for pharmacies. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Philadelphia, PA. Poster Presentation. Aug 2019.
29. **Tadrous M**, McCormack D, Martins D, Gomes T, Kwong J, Buchan S, Antoniou T. Impact of the publicly funded herpes zoster immunization program on burden of disease in Ontario, Canada. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Oral Presentation. Aug 2019.
30. **Tadrous M**, Fung K, Desveaux L, Gomes T, Taljaard M, Ivers N. Appropriate prescribing in nursing homes demonstration project: A pragmatic, cluster-randomized trial. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Oral Presentation. Aug 2019.
31. **Tadrous M**, Greaves S, Paterson M, Watt J, Juurlink DN, Martins D, Mamdani MM, Gomes T. Use of Stimulants in Adults and Risk of Cardiovascular Events: A Multi-Design Approach. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Oral Presentation. Aug 2019.

Mina TADROUS

32. **Tadrous M**, Matta R, Greaves S, Juurlink DN, Mamdani M, Gomes T. Mirabegron and the Risk of Arrhythmias: A Population-Based Cohort Study. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Poster Presentation. Aug 2019.
33. Guan Q, Campbell T, Martins D, **Tadrous M**, Juurlink D, Paterson M, Mamdani M, Mock D, Gomes T. Assessing the impact of opioid prescribing guidelines for dentists in Ontario, Canada. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Poster Presentation. Aug 2019.
34. **Tadrous M**, Khuu W, Martins D, Juurlink DN, Paterson JM, Mamdani MM, Gomes T. Recent changes in the prevalence of rapid tapering of opioid doses in Ontario, Canada. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Poster Presentation. Aug 2019.
35. **Tadrous M**, Antoniou T, Gomes T, Greaves S, Manji S, Juurlink DN, Kennedy SH, Mamdani MM. Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and the Risk of Suicide: A Nested Case Control Study. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Philadelphia, PA. Poster Presentation. Aug 2019.
36. Marras C, Maclagan LC, Cheng Y, Visanji N, **Tadrous M**, Bronskill SE. What's old is new: using artificial intelligence to accelerate discovery of new treatments. Innovation in Aging. Poster Presentation. 2019 Nov;3 (Suppl 1):S16-7.
37. Martins D, McCormack D, **Tadrous M**, Gomes T, Kwong J, Mamdani M, Buchan S, Antoniou T. Impact of the publicly funded herpes zoster immunization program on burden of disease in Ontario, Canada. 2019 CAHSPR Scientific Conference, Halifax, Canada. Poster Presentation. 29-31 May 2019.
38. Guan Q, Campbell T, Martins D, **Tadrous M**, Juurlink D, Paterson M, Mamdani M, Mock D, Gomes T. Assessing the Impact of Dental Opioid Prescribing Guidelines in Ontario. 2019 CADTH Symposium, Edmonton, Canada. Poster Presentation. Apr 2019.
39. Guan Q, Khuu W, Martins D, **Tadrous M**, Gomes T. Evaluating the Impact of Delisting High Strength Opioids on Opioid Use in Ontario. 2018 Canadian Association for Health Services and Policy Research Conference, Montreal, Canada. Oral Presentation. 29-31 May 2018.
40. Guan Q, Khuu W, Martins D, **Tadrous M**, Chiu M, Do M, Gomes T. Evaluating the Impact of Delisting High-Strength Opioids on Prescribing Patterns in Ontario, Canada. International Society of Pharmacoepidemiology's 2018 Mid-Year Meeting, Toronto, Canada. Poster Presentation. 21-24 Apr 2018.
41. Pasricha S, **Tadrous M**, Khuu W, Juurlink D, Mamdani M, Paterson M, Gomes T. (2018) Clinical indications for initiating opioids for pain management in Ontario, Canada: A population-based cohort study. Canadian Agency for Drugs and Technology in Health Symposium, Halifax, NS, Canada. Oral Presentation. 15-17 Apr 2018.
42. **Tadrous M**, Fung K, Desveaux, L., Taljaard, M., Gomes, T., Ivers, N. M. Use of Health Administrative Claims Data in a Pragmatic Clinical Trial of Academic Detailing to Improve Prescribing. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Montreal, QC, Canada. Oral Presentation. Apr 2018.
43. **Tadrous M**, Greaves S, Martins D, Nadeem K, Singh S, Auger C, Gomes T. Evaluation of the Fentanyl Patch-for-Patch Program in Ontario, Canada. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Montreal, QC, Canada. Oral Presentation. Aug 2017.

Mina TADROUS

44. Black CD, McCarthy L, Gomes T, Mamdani MM, Juurlink DN, **Tadrous M**. Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Montreal, QC, Canada. Poster Presentation. Aug 2017.
45. Guan Q, Khuu W, Spithoff S, Kiran T, Kahan M, **Tadrous M**, Martins D, Leece P, Gomes T. (2017). Patterns of Physician Prescribing for Opioid Maintenance Therapy in Ontario, Canada. International Conference for Pharmacoepidemiology, Montreal, Quebec. Poster Presentation.
46. Black C, Fernandes K, **Tadrous M**, Martins D, Hermann N, Gomes T. (2017). Adherence of Elderly Dementia Patients to Antipsychotic Treatments in Ontario. International Conference for Pharmacoepidemiology, Montreal, Quebec. Poster Presentation.
47. Khuu W, Martins D, **Tadrous M**, Yao Z, Singh S, Paterson M, Mamdani MM, Juurlink DN, Gomes T. Potentially Inappropriate Prescriptions for Stimulant Medication for Treatment of Attention Deficit Hyperactivity Disorder Among Canadian Adults. *Pharmacoepidemiology and Drug Safety*. 2016. 25(suppl. 3) 208.
48. Kiran T, Spithoff S, Khuu W, **Tadrous M**, Guan Q, Martins D, Leece P, Kahan M, Gomes T. Quality of Primary Care for Patients on Opioid Maintenance Therapy in Ontario, Canada. North American Primary Care Research Group Annual Meeting, Colorado Springs, USA. Oral Presentation. 12-16 Nov 2016.
49. **Tadrous M**, Khuu W, Lebovic G, Stanbrook M, Martins D, Paterson JM, Mamdani M, Juurlink DN, Gomes T. Real-world effectiveness of omalizumab for the treatment of severe asthma. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Dublin, Ireland. Poster Presentation. Aug 2016.
50. **Tadrous M**, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. Varenicline and Risk of Self-Harm: A Nested Case-Control Study. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Dublin, Ireland. Poster Presentation. Aug 2016.
51. Singh S, Khuu W, **Tadrous M**, Martins D, Mamdani MM, Elterman D, Gomes T. Comparative Adherence of Overactive Bladder Agents Among Older Patients. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Dublin, Ireland. Poster Presentation. Aug 2016.
52. Martins D, **Tadrous M**, Paterson M, Shah BR, Mamdani MM, Tu Jm Chu A, Juurlink DN, Singh S, Gomes T. The Impact of a Blood Glucose Test Strip Quantity Limit Policy on Clinical Outcomes. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Dublin, Ireland. Oral Presentation. Aug 2016.
53. Ban J, **Tadrous M**, Cicinelli E, Dubins D, Cadarette S. The diffusion of indirect comparison meta-analytic methods in the study of drugs: A systematic review and co-authorship network analysis. Accepted for oral presentation, Canadian Association for Health Services and Policy Research Annual Meeting, Toronto, Ontario. Poster Presentation. May 2016.
54. Wong WL, Pechlivanoglou P, Erman A, Saeed Y, **Tadrous M**, Younis M, Rayad NZ, Bielecki JM, Rac VE, Krahn M. Current Treatment for Chronic Hepatitis B (CHB): A Systematic Review and Network Meta-analysis. Society for Medical Decision Making, St. Louis, Missouri, USA. Poster Presentation. Oct 2015.
55. **Tadrous M**, Martins D, Yao Z, Singh S, Stanbrook M, Juurlink DN, Mamdani M, Gomes T. Comparative Adherence of ICS/LABA Products in Elderly Asthma Patients. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Poster Presentation. Aug 2015.

Mina TADROUS

56. Amiche MA, Albaum JM, **Tadrous M**, Pechlivanoglou P, Adachi JD, Levesque LE, Cadarette SM. Efficacy of Osteoporosis Pharmacotherapies in Preventing Fractures among Chronic Oral Glucocorticoids Users: A Network Meta-analysis. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Poster Presentation. Aug 2015.
57. Martins D, **Tadrous M**, Yao Z, Shah BR, Juurlink DN, Mamdani M, Gomes T. Appropriateness and Persistence of Testosterone Replacement Therapy in the Public Payer System. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Oral Presentation. Aug 2015.
58. Fernandes KA, **Tadrous M**, Martins D, Yao Z, Singh S, Herrmann N, Juurlink DN, Mamdani M, Gomes T. Determining exposure of newly initiated antipsychotic medication in a cohort of elderly dementia patients. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Poster Presentation. Aug 2015.
59. **Tadrous M**, Martins D, Yao Z, Fernandes KA, Herrmann N, Juurlink DN, Mamdani M, Gomes T. Regional and Setting Variation of Antipsychotic Prescribing to Elderly Patients Across Ontario. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Poster Presentation. Aug 2015.
60. Knowles S, **Tadrous M**, Martins D, Gomes T, Juurlink DN, Mamdani M. Using Pharmacoepidemiologic Studies to Inform Drug Policy. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Boston, MA, USA. Oral Presentation. Aug 2015.
61. Burden AM, Wong L, **Tadrous M**, Liu YY, Cadarette SM. Shiny and new: Uptake and persistence of new osteoporosis drugs. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Taipei, Taiwan. Poster Presentation. Oct 2014.
62. **Tadrous M**, Mamdani MM, Juurlink DN, Krahn M, Lévesque LE, Cadarette SM. Looking both ways before using the Disease Risk Score (DRS): Performance of the DRS in a cohort with known selection bias. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Taipei, Taiwan. Poster Presentation. Oct 2014.
63. Fraser LA, Albaum J, **Tadrous M**, Burden AM, Shariff S, Cadarette SM. Brand-Name vs. Generic Oral Bisphosphonate Medications Prescribing Patterns and Variations over Eleven years. American Society for Bone and Mineral Research Annual meeting. Houston, Texas, USA. Poster Presentation. Sep 2014.
64. Burden AM, Wong L, **Tadrous M**, Liu YY, Cadarette SM. Zoledronic Acid and Denosumab Use in Ontario, Canada. American Society for Bone and Mineral Research Annual meeting, Houston, Texas, USA. Poster Presentation. Sep 2014.
65. Amiche MA, Albaum JM, **Tadrous M**, Cadarette SM. Assessment of evidence gaps in glucocorticoid-induced osteoporosis: A systematic Review. Accepted for presentation at the Canadian Association for Health Services and Policy Research 2014 Annual Conference, Toronto, Ontario. Poster Presentation. May 2014.
66. Burden AM, **Tadrous M**, Wong L, Calzavara A, Y Liu, Cadaratte SM. Shiny and new: uptake and persistence with non-oral osteoporosis medications in Ontario, Canada. Health Policy. 2014. Canadian Association for Healthcare Policy Research annual Conference, Toronto, Ontario. Poster Presentation. 12-15 May 2014.
67. Burden AM, **Tadrous M**, Wong L, Calzavara A, Y Liu, Cadaratte SM. Shiny and new: uptake and persistence with non-oral osteoporosis medications in Ontario, Canada [Abstract] Osteoporos Int. 2014. World Congress of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Seville, Spain. Poster Presentation. 2-5 Apr 2014.

Mina TADROUS

68. **Tadrous M**, Wong L, Juurlink DN, Krahn M, Lévesque LE, Mamdani MM, Cadarette SM. Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-Analysis. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Montreal, Quebec. Poster Presentation. Aug 2013.
69. Edwards PR, Consiglio G, **Tadrous M**, Cadarette SM. Uptake of methodological innovation in pharmacoepidemiology: disease risk score co-authorship network analysis. International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Montreal QC. Poster Presentation. Aug 2013.
70. Burden AM, Huang A, **Tadrous M**, Cadarette SM. Variation in the days supply field for osteoporosis medications in Ontario. American Society for Bone and Mineral Research Annual Meeting, Minneapolis, Minnesota, USA. Poster Presentation. Oct 2012.
71. **Tadrous M**, Gagne JJ, Sturmer T, Cadarette SM. Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations. 28th Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain. Poster Presentation. Aug 2012.
72. Burden AM, Huang A, **Tadrous M**, Cadarette SM. Variation in the days supply field for osteoporosis medications in Ontario. 28th Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain. Poster Presentation. Aug 2012.
73. **Tadrous M**, Gagne JJ, Sturmer T, Cadarette SM. Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations. J Popul Clin Pharmacol;19: e118. Oral Presentation: Canadian Association of Population Therapeutics 2012 Annual Conference, Montreal, Quebec. Poster Presentation. May 2012.
74. Burden AM, Huang A, **Tadrous M**, Cadarette SM. Variation in the days supply field for osteoporosis medications in Ontario. J Popul Clin Pharmacol;19: e126. Oral Presentation: Canadian Association of Population Therapeutics 2012 Annual Conference, Montreal, Quebec. Poster Presentation. May 2012.
75. **Tadrous M**, McKinnon B. Survey of Medical Information practices in Canada and the United States. Drug Information Association Annual Canadian Meeting, Ottawa, Ontario. Poster Presentation. Nov 2010.
76. **Tadrous M**, Gharbawy DE, Hurley A, Miller B, Suda KJ. Establishing a Complete Drug Information Triad: Academic, Industry, and Hospital Training. American Society of Health System Pharmacist Summer Meeting, Florida, USA. Poster Presentation. Poster Presentation. Jun 2010.
77. Jones J, **Tadrous M**, Miller B, Hashimoto J. Pandemic Preparedness of Medical Information Departments that support Influenza Vaccines. Drug Information Association Workshop on Medical Communication, Scottsdale, Arizona, USA. Poster Presentation. Mar 20210.
78. Oester AE, Sahu P, Fleming JC, **Tadrous M**. Radiographic Predictors of Visual Outcome in Orbital Compartment Syndrome. The Association for Research in Vision and Ophthalmology, Palm Beach, Florida, USA. Poster Presentation. Feb 2010.
79. Knechtel L, Adhikari N, Alleyne C, Tawfik S, Macdonald J, Geerts W, Sever J, **Tadrous M**, Pinto R. Evaluation of a novel post-operative anticoagulation protocol in cardiovascular surgery. Canadian Council of Cardiovascular Nurses Annual Sessions. Toronto, Ontario. Poster Presentation. Oct 2008.
80. Meek PD, Evang S, **Tadrous M**, Triller D. Gastrointestinal tolerability of anticholinergic drugs for treatment of overactive bladder compared to placebo: a systematic review and meta-analysis. Digestive Disease Week, San Diego, California, USA. Poster Presentation. May 2008.

Editorials

1. Zhang P, **Tadrous M**. How pharmacist prescribing can alleviate health-care system pressures. Policy Options. 31 May 2022. <https://policyoptions.irpp.org/magazines/may-2022/pharmacists-prescribing-savings/>. **Co-Principal Author**.
2. Tadrous M, Gomes T, Law M. Pharmaceutical costs are soaring due to innovative but pricey new drugs. Globe and Mail. 2 Dec 2021. <https://www.theglobeandmail.com/opinion/article-pharmaceutical-costs-are-soaring-due-to-innovative-but-pricey-new/>. **Co-Principal Author**.
3. Hayes K, Tadrous M. The name game: A call for change to psychopharmacological nomenclature in clinical practice. BMJ Opinion. 12 Nov 2019. <https://blogs.bmj.com/bmj/2019/11/12/name-game-call-change-psychopharmacological-nomenclature-clinical-practice/>. **Co-Principal Author**.
4. Tadrous M, Burden A. Shaping with Data: Using Pharmacoepidemiology to Shape Pharmaceutical Policy and Clinical Decision-Making. Frontiers in Research. 22 Aug 2019. <https://www.frontiersin.org/research-topics/25582/shaping-with-data-using-pharmacoepidemiology-to-shape-pharmaceutical-policy-and-clinical-decision-ma>. **Co-Principal Author**.

Broadcast Interviews

1. “Why Canada ran short of children's Tylenol — and why it could happen again.” 14 Dec 2022. <https://financialpost.com/news/economy/why-canada-ran-short-of-childrens-tylenol-and-why-it-could-happen-again>
2. “Shortage of children’s medicine now extending to adult drugs.” CBC Canada Tonight. 17 Nov 2022. https://cbchls.akamaized.net/delivery/news/2022/11/17/Mina-Tadrous-nov16-19-41-35/Mina-Tadrous-nov16_5000kbps.mp4
3. “Parents scrambling amid shortage of medication for kids.” CBC The Current and Metro Morning.” 8 Nov 2022. <https://www.cbc.ca/listen/live-radio/1-63-the-current/clip/15947346-parents-scrambling-amid-shortage-medication-kids>
4. “Concerns over access to Paxlovid in Ontario.” CTV News. 14 Apr 2022. <https://barrie.ctvnews.ca/video?clipId=2422015>
5. “More people are turning to melatonin to sleep. But experts say it’s not a panacea for everyone.” CBC Radio News. 24 Feb 2022. <https://ici.radio-canada.ca/rci/en/news/1863973/more-people-are-turning-to-melatonin-to-sleep-but-experts-say-its-not-a-panacea-for-everyone>
6. “Scientists say COVID-19 booster intake is waning, urge Canadians to book their shots.” CBC News. 30 Jan 2022. <https://www.ctvnews.ca/health/coronavirus/scientists-say-covid-19-booster-intake-is-waning-urge-canadians-to-book-their-shots-1.5760910>
7. “The life-saving decisions inside an Ontario ICU.” CBC News. 20 Jan 2022. <https://www.cbc.ca/player/play/1994482243585>
8. “Doctors in Ontario are prescribing lower amounts of opioids.” CBC Radio (6 different cities). 23 Aug 2017. <http://www.cbc.ca/listen/shows/ottawa-morning/segment/13790393>

Text Interview: Acknowledged in Publication (Not Author)

1. "Paxlovid still offers high-risk COVID-19 patients protection against hospital admissions, study says." Globe and Mail. 13 Feb 2023. <https://www.theglobeandmail.com/canada/article-a-new-canadian-study-found-that-high-risk-covid-19-patients-treated/>
2. "Paxlovid should only be prescribed to those with COVID that are high risk of severe outcomes: study." Toronto Star. 13 Feb 2023. <https://www.thestar.com/news/canada/2023/02/13/paxlovid-should-only-be-prescribed-to-those-with-covid-that-are-high-risk-of-severe-outcomes-study.html>
3. "Health Canada reviewing safety of controversial breastfeeding drug." CBC News. 30 Jan 2023. <https://www.cbc.ca/news/canada/breastfeeding-lactation-drug-domperidone-health-canada-1.6731315>
4. "Explainer: Pharmacists address questions over new prescribing powers in Ontario." Toronto Star. 21 Jan 2023. https://www.thestar.com/life/health_wellness/2023/01/21/explainer-pharmacists-address-questions-over-new-prescribing-powers-in-ontario.html
5. "Imports of kids' pain and fever meds are coming, but critics say supply is fragile." Toronto Star. 10 Nov 2022. <https://www.thestar.com/business/2022/11/10/imports-of-kids-pain-and-fever-meds-are-coming-but-critics-say-supply-is-fragile.html>
6. "Does cannabis work as a sleep aid? We asked experts about three popular remedies?" Toronto Star. 31 Oct 2022. https://www.thestar.com/life/health_wellness/2022/10/31/does-cannabis-work-as-a-sleep-aid-we-asked-experts-about-three-popular-remedies.html?rf
7. "Tips for parents on the hunt for kids' fever-reducing meds." CBC News 4 Oct 2022. <https://www.cbc.ca/news/health/fever-medication-children-babies-1.6604259>
8. "Antibiotic Use Varies Across Canada's Provinces." Medscape 13 Apr 2022. <https://www.medscape.com/viewarticle/972013>
9. "First Canadian vaccine approved for COVID." Toronto Star. 24 Feb 2022. <https://www.thestar.com/news/gta/2022/02/24/first-canadian-vaccine-approved-for-covid.html>
10. "Switch to biosimilar drugs may save N.S. millions of dollars." CBC News. 4 Feb 2022. <https://www.cbc.ca/news/canada/nova-scotia/switch-to-biosimilars-may-save-ns-millions-of-dollars-1.6340494>
11. "Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments." US Health Day News. 28 Oct 2021. <https://www.usnews.com/news/health-news/articles/2021-10-28/use-of-ritalin-other-stimulants-can-raise-heart-risks-for-older-adults>
12. "Use of stimulants in older adults associated with higher risk for cardiovascular events in first month." Medical Xpress. 25 Oct 2021. <https://medicalxpress.com/news/2021-10-older-adults-higher-cardiovascular-events.html>
13. "Stimulants Linked to Early Risk of CV Events in Elderly." TCTMD. 25 Oct 2021. <https://www.tctmd.com/news/stimulants-linked-early-risk-cv-events-elderly>

14. "Use of stimulants in older adults associated with higher risk for cardiovascular events in first month." Eureka Alert and California News Times. 25 Oct 2021. <https://www.eurekaalert.org/news-releases/932619> | <https://californianewstimes.com/use-of-stimulants-in-older-adults-associated-with-higher-risk-for-cardiovascular-events-in-first-month/570165/>
15. "Antidepressant use among youth is skyrocketing across Canada. Prescribing doctors say they have little choice as teens 'can't wait nine months' for therapy." Toronto Star. 26 Apr 2021. <https://www.thestar.com/news/investigations/2021/04/26/more-kids-on-antidepressants-in-canada-than-ever-before-prescribing-doctors-say-they-have-little-choice-as-youth-cant-wait-nine-months-for-therapy.html>
16. "More drug shortages are inevitable unless we act now." Globe & Mail. 19 Oct 2020. <https://www.theglobeandmail.com/opinion/article-more-drug-shortages-are-inevitable-unless-we-act-now/>
17. "Inhalers, blood pressure meds top list of drug shortages reported by Canadian pharmacists." CTV News. 27 May 2020. <https://www.ctvnews.ca/health/inhalers-blood-pressure-meds-top-list-of-drug-shortages-reported-by-canadian-pharmacists-1.4956946>
18. "Drug supply chain could still be interrupted because of COVID-19." CBC News. 5 May 2020. <https://www.cbc.ca/news/canada/new-brunswick/covid-drug-supply-interruptions-1.5555800>
19. "Coronavirus a 'wake-up call' for Canada's prescription drug supply." CBC News. 27 Mar 2020. <https://www.cbc.ca/news/health/covid-19-drug-supply-1.5511659>
20. "Canada faces shortage of heartburn drug Pepcid after Zantac recall." CBC News. 15Jan2020. <https://www.cbc.ca/news/health/pepcid-shortage-canada-zantac-recall-1.5426862>
21. "Antidepressant prescribing for Canadian youth has increased: study." CTV News. 11 Jan 2020. <https://www.ctvnews.ca/health/antidepressant-prescribing-for-canadian-youth-has-increased-study-1.4763431>
22. "Popular Heartburn Drugs May Up Odds of Stomach Bug." US News. 27 Nov 2019. <https://www.usnews.com/news/health-news/articles/2019-11-27/popular-heartburn-drugs-may-up-odds-of-stomach-bug>
23. "What would Frederick Banting think?" Maclean's Magazine. 13 Aug 2019. <https://archive.macleans.ca/article/2019/9/1/what-would-frederick-banting-think>
24. "No Real-World CV Risk for Newer Overactive Bladder Drug- Observational study doesn't support risk seen in trials." MedPageToday. 16 Jul 2019. <https://www.medpagetoday.com/cardiology/prevention/81045>
25. "London area ranks third in province for naloxone distribution rate." London Free Press. 06 Jun 2019. <https://lfpres.com/news/local-news/london-area-ranks-third-in-province-for-naloxone-distribution-rate>
26. "Pharmacies selling DNA tests to help patients pick best medications." CBC National News. 25 Oct 2018. <https://www.cbc.ca/news/health/consumer-genetic-testing-for-medications-1.4876785>
27. "It's not just the EpiPen. Canada had 25 new drug shortages this week alone." CBC National News. 08 Sep 2018. <https://www.cbc.ca/news/health/second-opinion-drug-shortages180908-1.4815355>

Mina TADROUS

28. "Prescriptions led to 1 in 3 opioid deaths in Ontario in 2016, study says." CBC National News Network. 29 Aug 2018. <https://www.cbc.ca/news/health/opioid-deaths-1.4803238>
29. "More than half a million prescription drugs are stolen each year - and most are opioids." CBC National News. 27 Jun 2018. <https://www.cbc.ca/news/canada/missing-drugs-pharmacies-part1-1.4708041>
30. "Use of 'catastrophic' drug plan surges in Ontario, study says." The Globe and Mail. 26 Mar 2018. <https://www.theglobeandmail.com/canada/article-use-of-catastrophic-drug-plan-surges-in-ontario-study-says/>
31. "Number of people using catastrophic drug coverage has tripled, Ontario study finds." CBC News. 26 Mar 2018. <http://www.cbc.ca/news/health/catastrophic-drug-coverage-1.4593581>
32. "On the pill: How society tries to control the moods of women with drugs." The Globe and Mail. 09 Mar 2018. <https://www.theglobeandmail.com/opinion/article-on-the-pill-how-society-tries-to-control-the-moods-of-women-with/>
33. "Doctor wants to stop 'sticker shock' for patients picking up prescriptions." CBC News. 19 Dec 2017 <http://www.cbc.ca/news/health/drug-cost-surprises-1.4454803>
34. "The Danger of Putting Youth on Antidepressants: Why medication shouldn't be the default treatment for our kids' mental health." The Walrus. 20 Sep 2017. <https://thewalrus.ca/the-number-of-youth-taking-antidepressants-is-growing-but-are-the-drugs-working/>
35. "Should markups on high-cost drugs be capped." Healthy Debate. 2 Dec 2016. <http://healthydebate.ca/2016/12/topic/markup>
36. "Canadian Children Now Take Far More Mood-altering Drugs, Prescription Count Shows." National Post. 13 Nov 2016. <http://news.nationalpost.com/health/canadian-children-now-take-far-more-mood-altering-drugs>
37. "Why doctors choose the cheapest over-the-counter drugs." CBC. 18 Dec. 2015. <http://www.cbc.ca/news/health/branded-generic-medicine-consumers-1.3372409>
38. "Fewer hospital staff on weekends puts some patients at risk." Healthy Debate. 1 Aug 2013. <http://healthydebate.ca/2013/08/topic/quality/fewer-hospital-staff-on-weekends-puts-some-patients-at-risk>

D. Presentations and Special Lectures

1. INTERNATIONAL

Invited Presentations

- | | |
|----------|--|
| 2023 Jun | Invited Speaker. European Drug Utilization research Group Conference. Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries. Bologna, Italy. |
| 2022 Jun | Invited Speaker. SISPE x The Academic Council. Utilizing Social Media to Advance Your Career as a Pharmacoepidemiologist. Virtual Panel. Florida, USA. |

Mina TADROUS

- 2020 Nov **Invited Speaker.** Seminars on Drug Discovery and Development. Data-driven approaches to improve antibiotic prescribing. Zurich, Switzerland.
- 2020 Nov **Invited Speaker.** International Society of Pharmacoepidemiology (ISPE). Methods to evaluate the effects of policy changes during the opioid crisis. Virtual Panel. Maryland, USA.
- 2020 Oct **Invited Speaker.** International Society of Pharmacoepidemiology (ISPE). Measuring the impact of the COVID-19 Pandemic on Drug Utilization in Ontario. Virtual Panel. Maryland, USA.
- 2017 Aug **Invited Speaker.** International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Evaluation of the Fentanyl Patch-for-Patch Program in Ontario, Canada. Montreal, Quebec, Canada.
- 2017 Aug **Invited Speaker.** International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Control Yourself: Guidance for the Application and Reporting of Self-Controlled Study Designs in Pharmacoepidemiology. Montreal, Quebec, Canada.
- 2017 Aug **Invited Speaker.** International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Making it Count: Using Drug Utilisation to Inform Drug Policy-Introduction to Drug Utilization pre-conference Workshop. Montreal, Quebec, Canada.
- 2016 Aug **Invited Speaker.** International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Catch the Wave: Diffusion of Methodological Innovation in Pharmacoepidemiology. Dublin, Ireland.
- 2015 Aug **Invited Speaker.** International Conference in Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting. Using Pharmacoepidemiologic Studies to Inform Drug Policy. Boston, Massachusetts, USA.
- 2010 Apr **Invited Speaker.** Memphis-Area Invitational Pharmacy Residents' Conference – St. Jude Children's Research Hospital. Novel Analysis of Year-to-Year Reporting Sensitivity of Guillan-Barre after Influenza Immunization in Canada. Memphis, Tennessee, USA.
- 2010 Feb **Invited Speaker.** University of Tennessee Health Science Center-College of Pharmacy Graduate Seminar. Statin Use and Fracture Risk: Verdict of a Hung Jury. Memphis, Tennessee, USA.
- 2009 Oct **Invited Speaker.** Drug Information Group Keynote- American College of Clinical Pharmacy Annual Meeting. Utilizations and Applications of Disease Risk Scores: Systematic Review. Anaheim, California, USA.
- 2009 Apr **Invited Speaker.** Memphis-Area Invitational Pharmacy Residents' Conference – St. Jude Children's Research Hospital. Assessing the sensitivity and characteristics of the Canadian National Vaccine Adverse Event Reporting System. Memphis, Tennessee, USA.
- 2009 Feb **Invited Speaker.** University of Tennessee Health Science Center-College of Pharmacy Graduate Seminar. Canadian Health Care System: A Brief Overview. Memphis, Tennessee, USA.
- 2008 Oct **Invited Panelist.** University of Tennessee Health Science Center-College of Pharmacy Graduate Seminar. Pharmacovigilance: A Tool of Public Safety. Memphis, Tennessee, USA.

Special Lectures

- 2022 Aug **Presenter.** Poster presented to International Conference on Pharmacoepidemiology (ICPE 2022) "Agreement and Correlation Between Different Topical Corticosteroid Potency

Mina TADROUS

Classification Systems". Copenhagen, Denmark.

- 2022 Aug **Presenter.** Poster presented to International Conference on Pharmacoepidemiology (ICPE 2022) "Impact of the COVID-19 Controlled Drugs and Substances Act Exemption on Pharmacist Prescribing of Opioids and Benzodiazepines in Ontario: A Cross-Sectional Time-Series Analysis". Copenhagen, Denmark.
- 2022 Aug **Presenter.** Poster presented to International Conference on Pharmacoepidemiology (ICPE 2022) "International Trends in Prescription Opioid Sales Among Developed and Developing Countries Prior To, and During The COVID-19 Pandemic: A Cross-Sectional Analysis of 66 Countries". Copenhagen, Denmark.
- 2022 Aug **Presenter.** Poster presented to International Conference on Pharmacoepidemiology (ICPE 2022) "Global Extent of The Valsartan Drug Recall and Its Effect on Antihypertensive Drug Use: A Multi-National Study". Copenhagen, Denmark.
- 2022 Aug **Presenter.** Poster presented to International Conference on Pharmacoepidemiology (ICPE 2022) "Risk of SARS-CoV-2 Infection Following Initial COVID-19 Vaccination by Location". Copenhagen, Denmark.
- 2022 Jan **Presenter.** Lecture presented to the University of Hong Kong Department of Pharmacology and Pharmacy "Critical Appraisal of RCTs and Meta-analysis". Pok Fu Lam, Hong Kong.
- 2010 Feb **Presenter.** Meta-Analysis. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2010 Jan **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2010 Jan **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2010 Jan **Presenter.** Biostatistics. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 Nov **Presenter.** Journal Club Recitation Exercises. Conducted recitation session in small groups with third-year University of Tennessee PharmD students. Memphis, Tennessee, USA.
- 2009 Nov **Presenter.** Globalization in Healthcare. Conducted recitation session in small class with first-year University of Tennessee PharmD students. Memphis, Tennessee, USA.
- 2009 Nov **Presenter.** Adverse Event Reporting and Analyzing Case Reports. Lecture presented to third-year University of Tennessee PharmD students. Memphis and Knoxville, Tennessee, USA.
- 2009 Oct **Presenter.** Clinical Trial Methodology: Randomization, Blinding and Controls. Lecture presented to third-year University of Tennessee PharmD students. Memphis and Knoxville, Tennessee, USA.
- 2009 Oct **Presenter.** Model Journal Club. Lecture presented to third-year University of Tennessee PharmD students. Memphis and Knoxville, Tennessee, USA.
- 2009 May **Presenter.** Meta-Analysis. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis,

Mina TADROUS

Tennessee, USA.

- 2009 May **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 May **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 May **Presenter.** Biostatistics. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 Apr **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 Mar **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 Feb **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2009 Jan **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2008 Nov **Presenter.** Journal Club Recitation Exercises. Conducted recitation session in small groups with third-year University of Tennessee PharmD students. Memphis, Tennessee, USA.
- 2008 Oct **Presenter.** Clinical Trial Methodology: Randomization, Blinding and Controls. Lecture presented to third-year University of Tennessee PharmD students. Memphis and Knoxville, Tennessee, USA.
- 2008 Oct **Presenter.** Model Journal Club. Lecture presented to third-year University of Tennessee PharmD students. Memphis and Knoxville, Tennessee, USA.
- 2008 Aug **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2008 Aug **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2008 Jul **Presenter.** FDA Approval Process. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2008 Jul **Presenter.** Clinical Trial Design. Lecture presented to fourth-year University of Tennessee PharmD students on rotation at the University of Tennessee Drug Information Center. Memphis, Tennessee, USA.
- 2008 Apr **Presenter.** Heart Failure-Medication Therapy Management. Conducted recitation session in

Mina TADROUS

large groups with second-year University of Tennessee PharmD students. Memphis, Tennessee, USA.

2008 Apr **Presenter.** Dealing with Ethnic Diversity in Practice. Conducted recitation session in small class with third-year University of Tennessee PharmD students. Memphis, Tennessee, USA.

2. NATIONAL

Invited Presentations

- 2023 Oct **Invited Speaker.** Annual Market Access Summit. COLLABORATING ON RWE: Improve your Submissions through Better Collaboration on Gathering Real World Evidence to Support Better Quality Decisions. Toronto, Ontario, Canada
- 2023 May **Invited Speaker.** Health Canada CED Retreat. Presenting on behalf of Canada's Drug and Health Technology Agency (CADTH) on Real-World Evidence (RWE) for Decision-Making. Toronto, Ontario, Canada
- 2023 Mar **Invited Speaker.** Pandemic Instrument Partner and Stakeholder Engagement Forum. The views and perspectives gathered during the Forum will serve to provide important considerations for federal officials and help to inform the development of the Government of Canada's priorities and positions in the development of a pandemic instrument under the World Health Organization. Ottawa, Ontario, Canada
- 2022 Jan **Invited Speaker.** Canadian Association for Population Therapeutics (CAPT) Virtual Conference - Pathways To Access & Reimbursement. How to Optimize Data and Health Resources to Support Patient Centred Decision-Making on New and Innovative Therapies. Toronto, Ontario, Canada.
- 2020 Nov **Invited Speaker.** Centre for Health Services and Policy Research. Impact of the COVID-19 pandemic on drug supply and utilization: Same but different. Vancouver, British Columbia, Canada.
- 2020 Nov **Invited Speaker.** 4th Pharmacoepidemiology Annual Virtual Workshop. Impact of the COVID-19 pandemic on drug supply and utilization: Same but different. Winnipeg, Manitoba, Canada.
- 2020 Nov **Invited Speaker.** 2020 Canadian Agency for Drugs and Technologies in Health Symposium. Measuring the Impact of the COVID-19 Pandemic on Drug utilization in Ontario, Canada. Toronto, Ontario, Canada.
- 2020 Oct **Invited Speaker.** Canadian Association for Population Therapeutics (CAPT) Virtual Conference. CADTH/CanREValue- Updates on the progress of RWE in Canada? Toronto, Ontario, Canada.
- 2020 Mar **Invited Speaker.** DSECT/DSEN Monthly Seminar Series. Rising tide of high-cost drugs: Current insights, policy implications and potential solutions. Toronto, Ontario, Canada.
- 2019 Apr **Invited Speaker.** 2019 CADTH Symposium. Bringing Citizen-Led Research to Life: Experiences of the Ontario Drug Policy Research Network Citizens' Panel Landscape of Prescription Stimulant Use Report. Edmonton, Alberta, Canada.
- 2018 Apr **Invited Speaker.** CADTH Symposium Workshop. Family Medicine Forum (FMF) 2018. From lingo to Application: Use of Confounder Summary Scores (Propensity and Disease Risk Scores) in Health Technology Assessment. Toronto, Ontario, Canada.

Mina TADROUS

- 2018 Oct **Invited Speaker.** Canadian Association for Population Therapeutics (CAPT) Conference. Use of RWE in Decision Making: Now & in the Future. Toronto, Ontario, Canada.
- 2018 Aug **Invited Speaker.** National Webinar for Canadian Agency for Drugs and Technologies in Health (CADTH). Using Real-World Evidence to Inform Drug Policy: Lessons & Examples from Ontario. Ottawa, Ontario, Canada.
- 2017 May **Invited Presenter.** DSECT Symposium. Incorporating the patient perspective into Drug Safety and Effectiveness Research. Toronto, Ontario, Canada.
- 2017 Apr **Invited Speaker.** CADTH Symposium. From lingo to Application: Use of Confounder Summary Scores (Propensity and Disease Risk Scores) in Health Technology Assessment. Ottawa, Ontario, Canada.
- 2016 Apr **Invited Speaker.** CADTH Symposium Workshop. From lingo to Application: Use of Confounder Summary Scores (Propensity and Disease Risk Scores) in Health Technology Assessment. Ottawa, Ontario, Canada.
- 2013 Nov **Invited Speaker.** Canadian Association of Population Therapeutics 2013 Annual Conference. Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-analysis. Toronto, Ontario, Canada.
- 2012 May **Invited Speaker.** Canadian Association of Population Therapeutics 2012 Annual Conference. Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations. Montreal, Quebec, Canada.

Special Lectures

- 2018 Oct **Presenter.** Partners in Research. Webinar presented to researchers and patients across Canada. Toronto, Ontario, Canada.
- 2018 Apr **Presenter.** Partners in Research. Webinar presented to researchers and patients across Canada. Toronto, Ontario, Canada.
- 2017 Oct **Presenter.** Partners in Research. Webinar presented to researchers and patients across Canada. Toronto, Ontario, Canada.

3. PROVINCIAL / REGIONAL

Invited Presentations

- 2021 Sep **Invited Speaker.** Hepatitis C in Ontario: Testing, Direct-Acting Antiviral Prescribing and Implications for Hepatitis C Elimination. Public Health Ontario Rounds. Toronto, Ontario, Canada.
- 2020 May **Invited Speaker.** Respiriology Rounds – Ottawa Hospital Research Institute. Drug Shortages and COVID: What we know and what we can do? Ottawa, Ontario, Canada.
- 2020 Mar **Invited Speaker.** CATIE (Canadian AIDS Treatment Information Exchange) webinar - Linking testing to treatment: Update on hepatitis C care in Ontario. Prescribing trends of Direct Acting Antivirals (DAAs) for the treatment of Hepatitis C in Ontario. Toronto, Ontario, Canada.
- 2019 Nov **Invited Speaker.** Ontario Telemedicine network Geriatric Addiction Rounds. Bitter Pills: The Burden of Polypharmacy on Older Adults. Toronto, Ontario, Canada.

Mina TADROUS

- 2019 Oct **Invited Speaker.** CATIE (Canadian AIDS Treatment Information Exchange) Ontario Provincial Meeting. Current Utilization of Direct Acting Antivirals in Ontario. Toronto, Ontario, Canada.
- 2019 Jun **Invited Speaker.** Star Alumni Talk – Graduate Research in Progress Workshop. University of Toronto. Stumbling Forward: Lessons learned and mistakes learned. Toronto, Ontario, Canada.
- 2019 Jun **Invited Speaker.** Ontario College of Pharmacists Symposium on Quality Indicators for Pharmacy. Prescription for the Future. Toronto, Ontario, Canada.
- 2019 May **Invited Lecturer.** 2019 Annual National Initiative for the Care of the Elderly (NICE) Knowledge Exchange. Bitter Pills: The Burden of Polypharmacy on Older Adults. Toronto, Ontario, Canada.
- 2016 Jan **Invited Speaker.** The Committee to Evaluate Drugs (CED) – Government of Ontario. 14. Chronic Hepatitis B- Results and Recommendations of a Drug class Review. Toronto, Ontario, Canada.
- 2015 Jan **Invited Speaker.** The Committee to Evaluate Drugs (CED) – Government of Ontario. Cognitive Enhancers for Alzheimer’s disease and Antipsychotics for Dementia. Toronto, Ontario, Canada.
- 2015 Jan **Invited Lecturer.** The Committee to Evaluate Drugs (CED) – Government of Ontario. 13. Testosterone Replacement Therapy: Results and recommendations of a Drug Class Review. Toronto, Ontario, Canada.

Special Lectures

- 2022 Jan **Presenter.** PHM310 “Pharmacy in the Modern Healthcare system”: a) Introduction to drug shortages b) Involving Patients in Research and healthcare decision making. Toronto, Ontario, Canada.
- 2022 Jan **Presenter.** HAD5306 “Introduction to Health Services Research Methods and the Use of Health Administrative Data”: Confounding, Risk Adjustment, and Causal Inference. Toronto, Ontario, Canada.
- 2015 Mar **Presenter.** Drug Class Reviews: Overview and Example. Webinar presented to ODPRN students across Ontario. Toronto, Ontario, Canada.

4. LOCAL

Invited Presentations

- 2023 May **Invited Speaker.** Women’s College Hospital – Medical Grand Rounds, Research and Innovation. Minor Ailment Services In Ontario Pharmacies: Myths, truths and future directions. Toronto, Ontario, Canada.
- 2019 Nov **Invited Speaker.** Centre for Practice Excellence – Leslie Dan Faculty of Pharmacy Speaker Series. Is pharmacy late to the party? The emergence of pharmacy data quality indicators. Toronto, Ontario, Canada.
- 2018 Oct **Invited Speaker.** Women’s College Hospital-WIHV Rounds. Rising Tide of High-cost Drugs: Current Insights, Policy Implications, and Potential Solutions. Toronto, Ontario, Canada.
- 2017 Sep **Invited Speaker.** ICES CDP Program Meeting. Use and users of Ontario's Trillium Drug Program. Toronto, Ontario, Canada.

Mina TADROUS

- 2017 Jun **Invited Speaker.** Drug Use Professional Specialists Group. Critical Appraisal 101: What a practicing pharmacist needs to know. Toronto, Ontario, Canada.
- 2017 Jan **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Self-controlled Study Designs in Pharmacoepidemiology Workshop. Toronto, Ontario, Canada.
- 2016 Nov **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Use of Confounder Summary Scores (Propensity and Disease Risk Scores) Toronto, Ontario, Canada.
- 2014 Apr **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Looking Both Ways before using the DRS: Performance of the Disease Risk Score in a Cohort with Known Selection Bias. Clinical, Social, and Administrative Pharmacy. Toronto, Ontario, Canada
- 2013 May **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-analysis. Clinical, Social, and Administrative Pharmacy. Toronto, Ontario, Canada.
- 2012 Jan **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Advancing Comparative Effectiveness Research: Filling in the Gaps for Bisphosphonates. Clinical, Social, and Administrative Pharmacy. Toronto, Ontario, Canada.
- 2010 Sep **Invited Speaker.** Leslie Dan Faculty of Pharmacy Seminar. Assessing the sensitivity of the Canadian Adverse Event Following Immunization Surveillance System (CAEFISS). Toronto, Ontario, Canada.

Special Lectures

- 2022 Jan **Presenter.** Administration of ICES Projects. Virtual workshop presented to Women's College Hospital researchers, staff, and trainees. Toronto, Ontario, Canada.
- 2019 Jul **Presenter.** Introduction to Health Economics and Real-world evidence. Translational Research program- University of Toronto. Toronto, Ontario, Canada.
- 2017 Mar **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2017 Feb **Presenter.** Pharmacovigilance and Case Report. Lecture presented to University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2017 Jan **Presenter.** Clinical Trial Design. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2016 Oct **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2016 Oct **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2016 Sep **Presenter.** Clinical Trial Design. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2016 Mar **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.
- 2016 Feb **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto "PharmD for Pharmacist" students. Toronto, Ontario, Canada.

Mina TADROUS

- 2016 Jan **Presenter.** Clinical Trial Design. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Oct **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Sep **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Sep **Presenter.** Clinical Trial Design. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Mar **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Feb **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2015 Jan **Presenter.** Clinical Trial Design. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2014 Nov **Presenter.** Pharmacovigilance and Case Report.. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2014 Sep **Presenter.** Pharmacists in Research. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2013 Oct **Presenter.** Pharmacovigilance and Case Report.. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2013 Sep **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2012 Nov **Presenter.** Pharmacists in Research. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2012 Nov **Presenter.** Pharmaceutical Research and Cells and Drugs. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2012 Oct **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2012 Oct **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2012 Sep **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2011 Nov **Presenter.** Pharmacists in Research. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2011 Nov **Presenter.** Meta-Analysis and Practice Guidelines. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2011 Oct **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.

Mina TADROUS

- 2011 Oct **Presenter.** Clinical Trial Design and Example Journal Club. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2011 Mar **Presenter.** Pharmaceutical Research and Cells and Drugs. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2010 Jul **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2010 Jul **Presenter.** Clinical Trial Design and Example Journal Club. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2009 Jul **Presenter.** Pharmacovigilance and Case Report. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.
- 2009 Jul **Presenter.** Clinical Trial Design and Example Journal Club. Lecture presented to the University of Toronto “PharmD for Pharmacist” students. Toronto, Ontario, Canada.

5. MEDIA APPEARANCES

- 2021 Oct University of Toronto Leslie Dan Faculty of Pharmacy. I’m Pharmacy Podcast Season 2: Lifecycle of a Drug <https://www.pharmacy.utoronto.ca/news-announcements/im-pharmacy-podcast-season-2-lifecycle-drug>
- 2022 Oct University of Toronto Leslie Dan Faculty of Pharmacy. I’m Pharmacy Podcast Season 3: Big problems, Bigger Solutions

E. Teaching and Design

1. INNOVATIONS AND DEVELOPMENT IN TEACHING AND EDUCATION

Teaching Philosophy

Introduction

My teaching philosophy is built on cornerstones developed from my own learning and teaching experiences. The four major foundations of my teaching philosophy are passion, active learning, development of strong student-teacher relationships and online education. Through my teaching, I aim to instill an understanding of epidemiological methods and critical appraisal skills in my students. I help to foster and develop future researchers, public health professionals, and clinicians who can conduct and understand research at the highest level. While I acknowledge that many of the students I teach will not go on to be academics or researchers, I wholeheartedly believe that all students must be able to evaluate and understand the literature in the fast-paced, ever-changing world of pharmacy practice, healthcare and public health.

Passion

Throughout my training, I have been motivated by a passion for pharmacoepidemiology; both its application and its translation to end-users, my patients. One of the primary reasons I chose to pursue a career academia was the opportunity to impact future researchers and clinicians. I strongly believe that passion is contagious. This transmittable passion instilled in me by my past educators and mentors has led me to where I am today, and I hope that I can pass this on through my teaching to my students. Mentoring students in the past has shown me the importance of finding and instilling a sense of passion in the importance of their work to drive them to achieve at the highest level.

Mina TADROUS

Active Learning

I am a strong supporter of active learning and have found that introductory courses in research methodology may seem irrelevant to students who have not yet applied these skills. Understanding the practical applications may be difficult for the students to learn, and even the use of real-world situations and examples does little to bridge this gap. Instead, I attempt to have more active participation through short exercises within my lectures. Only through practice will a real understanding and comfort with the material be developed. Although a structured approach can be valuable in quickly establishing foundational skills, providing additional exercises helps to entrench a deeper understanding beyond the basics. I apply some form of active learning activity in the majority of my lectures and throughout the courses I have developed.

Strong Relationships

I approach all of my relationships with students professionally but enjoy allowing my sense of humour and fun-loving attitude to shine through. I believe this makes for a relaxed learning environment that can catalyze open communication, creativity and mutual respect. Only through this sharing of humanity can the stage be set to foster learning and development that is long-lasting. This is valuable when working with graduate and experiential students as those relationships are long-term and need to be fostered to promote a productive and comfortable learning environment.

Online Learning

The development and implementation of online learning as a means of improving and broadening access to education is an important area of teaching for me. During my current time as Assistant Professor at the University of Toronto, I have developed the first-ever fully asynchronous online critical appraisal pharmacy course in Canada. I also worked to develop ODPRN's online training program in Drug Policy for members of the public and students. The development of these courses has allowed me to teach students and learners worldwide and prepare future clinical pharmacists who understand research methods and critical thinking. The use of online teaching has given me an opportunity to teach students who may not have had the chance to take courses due to their current life circumstances. The development of these courses is a constant learning process as the needs of students and technology change rapidly. I have developed a variety of techniques that combine both traditional didactic methods and active-learning methods, which allows for a blended learning environment. For example, allowing both the use of asynchronous discussion boards and establishing virtual office hours allows students to communicate with instructors in a means that matches their learning style and lifestyle. Lastly, the development of online course modules is an excellent tool for the development of materials that can also be integrated with traditional courses and be used to teach atypical audiences such as policymakers and patients.

Conclusion

I am a passionate educator and am committed to teaching students what I consider to be a unique and essential skill set in a fast-growing field. I sincerely hope that through various practical opportunities and blended teaching styles, I will help my students develop the necessary skills needed as they progress through their training.

F. Research Supervision

1. PRIMARY OR CO-PRIMARY SUPERVISION

Postdoctoral Research Fellow (Post-PhD)

2023 Jan – present

Primary Supervisor. Yasmin Abdul Aziz. Supervisee Institution: Women's College Hospital; Leslie Dan Faculty of Pharmacy, University of Toronto. Projects: 1. *Health System Impact Fellowship doctoral trainee (CIHR-IHSPR DRA)??*. *Data-driven quality improvement in Community Pharmacy: Developing Audit and feedback (A&F) interventions to improve pharmaceutical care*. 2. *Ontario Program to Improve*

Graduate Student Committee Membership

- **Shenthuraan Tharmarajah**
 - Degree: PhD
 - Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2023 - Ongoing

- **Yuti Patel**
 - Degree: PhD
 - Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2022 – Ongoing

- **Daphne To**
 - Degree: PhD
 - Primary Supervisor: Dr. Noah Ivers
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2022 – Ongoing

- **Araniy Santhireswaran**
 - Degree: MSc
 - Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2022 – Ongoing

- **Kevin Peters**
 - Degree: MA
 - Primary Supervisor: Dr. Mina Tadrous
 - Institution: University of British Columbia
 - Status 2022 - Ongoing

- **Alyssa Yang**
 - Degree: MSc
 - Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2021 – Ongoing

- **Jerome Flores**
 - Degree: MA
 - Primary Supervisor: Dr. Carlo DeAngelis
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status 2021 – Ongoing

- **Shanzeh Chaudhry**
 - Degree: MSc

Mina TADROUS

- Primary Supervisor: Dr. Mina Tadrous
- Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
- Status 2021 - Ongoing

- **Jasmine Carter**
 - Degree: PhD
 - Primary Supervisor: Dr. Micheline Piquette-Miller
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status: 2019 – Ongoing

- **Nima Tourchian**
 - Degree: MSc
 - Primary Supervisor: Dr. Tara Gomes
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status: 2019 – Ongoing

- **Lara Chayab**
 - Degree: PhD
 - Primary Supervisor: Dr. Murray Krahn
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: Leslie Dan Faculty of Pharmacy, University of Toronto
 - Status: 2019 – Ongoing

- **Seraphine Zeitouny**
 - Degree: PhD
 - Primary Supervisor: Dr. Michael Law
 - Co-Primary Supervisor: Dr. Mina Tadrous
 - Institution: School of Population and Public Health, Faculty of Medicine, University of British Columbia
 - Status: 2017 – Ongoing

Pharmacy Advanced Pharmacy Practice Experience (APPE) Students

Supervised pharmacy students on their research-elective rotations at the Leslie Dan Faculty of Pharmacy, University of Toronto. During their rotations or research electives, the students would work on projects related to the area of drug policy, pharmacoepidemiology or critical appraisal. All students had to complete presentations related to their topic. All students would have topic discussions related to systematic reviews and methods in pharmacoepidemiology.

- **Student Names:**

Mina TADROUS

1. Jenn Chai (University of Pittsburgh)
2. Salita Som (University of Bath)
3. Robin Gunning (University of Toronto)
4. Keqing Zhao (University of Toronto)
5. Hong Lu (University of Toronto)
6. Jennifer Fenna (University of Toronto)
7. Michael Crosby (University of Toronto)
8. Rola Hassan (University of Toronto)
9. Kaleen N. Hayes (University of Toronto)
10. Lindsay Wong (University of Toronto)
11. George Hanna (University of Toronto)
12. Sneha Gaitonde (University of Pittsburgh)
13. Donna Rahmatian (University of Toronto)
14. Aleksandra Trkulja (University of Toronto)

Summer and Elective Research Students at the University of Toronto and Women's College Hospital

Supervised pharmacy and graduate students at the University of Toronto and Women's College Hospital. During their three-to-four-month placement or research electives the students would work on projects related to the area of pharmacoepidemiology and aim to contribute to a publication. All students had to complete presentations related to their topic. Two of the international students had placements arranged in a variety of practice settings. All students would have topic discussions related to systematic reviews and methods in pharmacoepidemiology

- **Student Names:**

15. Araniy Santhireswaran (Summer 2022)
16. Setayesh Yazdani (Summer 2022)
17. Fred Abdel Malek (Summer 2022)
18. Katherine Saunders (Summer 2022)
19. Yuna Choi (Fall 2021)
20. Ashwinie Sivakumar (Summer 2021)
21. Tyler Scheider (Spring 2020)
22. Ann Chung (Spring 2020)

Mina TADROUS

- 23. Charlotte Boone (Fall 2020)
- 24. Maria Bolus (Fall 2020)
- 25. Natalia Konstantelos (Fall 2020)
- 26. Yina Xu (Spring 2017)
- 27. Nikita Arora (Summer 2016)
- 28. Cody Black (Summer/Fall 2013 and Summer 2017)
- 29. Joann Bann (Fall 2013)
- 30. Lindsay Wong (Summer 2012)
- 31. Sophie Raspoutine (Summer 2011)
- 32. Nathalie Vaucoret (Summer 2011)

Students at the College of Pharmacy University of Tennessee

Led and supervised three to four pharmacy students on their Drug Information rotation at the University of Tennessee Drug Information Center. During their 6-week placement, the students would be placed in the drug information center answering calls from healthcare providers from across the state. Students had to complete two journal clubs, a critical appraisal, and a review article of a topic. I also led ten topic discussions throughout their four to six-week placement on a variety of topics from clinical trials to literature reviews.

Total Number of Students: 20

2. OTHER SUPERVISION

Doctoral Research (PhD)

Committee Member – Thesis, External Reviewer

2022 May – present **PhD.** Abby Emdin. Supervisee Institution: Dalla Lana School of Public Health, University of Toronto. *Medication use in community-dwelling older adults with dementia in Ontario: Applying machine learning techniques to better describe CNS-active prescribing patterns over time.* Supervisor: Dr. Susan Bronskill

Graduate Research (MSc)

Committee Member – Thesis, Appraisal and Oral Examination

2022 May – present **MSc.** Andrea He. Supervisee Institution: Leslie Dan Faculty of Pharmacy, University of Toronto. *Thesis title.* Supervisor: **Name**

2022 May – present **MSc.** Claire Huang. Supervisee Institution: University of Illinois. *Thesis title.* Supervisor: **Name**

Mina TADROUS

2022 May – present

MSc. Laila Aboulatta. Supervisee Institution: University of Manitoba. *Thesis title.*
Supervisor: **Name**

2022 May – present

MSc. Roxana Tudor. Supervisee Institution: Leslie Dan Faculty of Pharmacy,
University of Toronto. *Thesis title.* Supervisor: **Name**

2022 May – present

MSc. Shaleesa Ledlie. Supervisee Institution: Leslie Dan Faculty of Pharmacy,
University of Toronto. *Thesis title.* Supervisor: **Name**

2022 May – present

MSc. Anna Rzepka. Supervisee Institution: Leslie Dan Faculty of Pharmacy,
University of Toronto. *Impact of the COVID-19 pandemic on timeliness of
denosumab dispensations in Ontario, Canada: An interrupted time series analysis.*
Supervisor: Dr. Suzanne Cadarette